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Enhancing neuronal chloride extrusion
rescues α2/α3 GABAA-mediated analgesia
in neuropathic pain
Louis-Etienne Lorenzo 1,2,13, Antoine G. Godin 1,3,4,13, Francesco Ferrini 1,3,4,5, Karine Bachand1,
Isabel Plasencia-Fernandez1,4, Simon Labrecque1, Alexandre A. Girard1,6, Dominic Boudreau1,4,
Irenej Kianicka7,12, Martin Gagnon 1,8, Nicolas Doyon1,9, Alfredo Ribeiro-da-Silva2,10,11 &
Yves De Koninck 1,2,3,4,11*
Spinal disinhibition has been hypothesized to underlie pain hypersensitivity in neuropathic
pain. Apparently contradictory mechanisms have been reported, raising questions on the best
target to produce analgesia. Here, we show that nerve injury is associated with a reduction in
the number of inhibitory synapses in the spinal dorsal horn. Paradoxically, this is accom-
panied by a BDNF-TrkB-mediated upregulation of synaptic GABAARs and by an α1-to-
α2GABAAR subunit switch, providing a mechanistic rationale for the analgesic action of
the α2,3GABAAR benzodiazepine-site ligand L838,417 after nerve injury. Yet, we demon-
strate that impaired Cl- extrusion underlies the failure of L838,417 to induce analgesia at high
doses due to a resulting collapse in Cl- gradient, dramatically limiting the benzodiazepine
therapeutic window. In turn, enhancing KCC2 activity not only potentiated L838,417-induced
analgesia, it rescued its analgesic potential at high doses, revealing a novel strategy
for analgesia in pathological pain, by combined targeting of the appropriate GABAAR-
subtypes and restoring Cl- homeostasis.
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Noxious and innocuous somatosensory inputs are segre-gated and filtered at the level of the superficial dorsalhorn (SDH) of the spinal cord by different inhibitory
mechanisms1. GABAA and glycine receptor-mediated transmis-
sion mechanisms have been shown to be largely involved in this
regulation. Thus, a deficit in GABAA and glycine signaling has
been identified as a primary mechanism underlying pathological
pain. Blocking inhibition, for example, replicates symptoms
resembling those observed in neuropathic pain patients2. Yet,
conflicting reports indicate that different determinants of the
strength of GABAA/glycine-mediated transmission may change
in opposing directions. Down-regulation of the K+–Cl− co-
transporter KCC2 has been reported in multiple studies3–7. In
contrast, what happens to GABAA and glycine signaling remains
controversial: global measurements of the number of inhibitory
interneurons, GABA levels, its synthesis enzyme glutamate acid
decarboxylase (GAD) or its vesicular transporter (VGAT) as well
as GABAA receptors (GABAARs) yield contradictory results8–18.
In addition, none of these measurements distinguishes changes in
pre- vs. postsynaptic inhibition—i.e., on nociceptive primary
afferent terminals vs. SDH neurons. Finally, they do not address
whether there is a change in the number of synaptic contacts
specifically onto SDH neurons and, in particular, if there is a
change in the total number of receptors per synapse. In a recent
study, we found a decrease in GABAergic terminals in the SDH
after peripheral nerve injury (PNI)15, but no systematic quanti-
tative studies on the nature and degree of receptor expression at
SDH synapses are available. This information is important to
assess the net functional impact of a deficit in Cl− homeostasis
resulting from KCC2 hypofunction19. To fill this gap, we per-
formed a detailed quantitative analysis of the GABAARs and
glycine receptors (GlyRs) on SDH neurons at inhibitory post-
synaptic sites. We used gephyrin labeling as a tool to define these
postsynaptic sites because we previously found that gephyrin
clusters are exclusively postsynaptic in the SDH, as they are
present on dorsal neurons but absent from primary afferent
terminals20,21.
We found a decrease in the number of inhibitory synapses on
SDH neurons after PNI. This decrease in number of synapses
was however associated with a synaptic scaling, as there was
after PNI an increase in GABAARs per remaining synapse
without any change in synaptic GlyRs. In addition, we found a
switch in GABAAR subunit composition towards enriched α2,3
GABAARs, which generate longer GABAergic mIPSCs22,23.
These seemingly opposing KCC2/GABAAR changes raised the
question of the best therapeutic strategy to adopt in such con-
ditions. We first tested the impact of targeting the α2,3
GABAARs with the positive modulator L838,41724. We found
that a single injection of this benzodiazepine site ligand pro-
duced an analgesic effect in PNI animals, but not in shams,
consistent with the switch towards α2,3 subunits after injury.
This switch in subunit composition thus provides a mechanistic
explanation for the analgesic action of α1-sparing benzodiaze-
pines25. Interestingly, at high doses of L838,417, we observed a
significant collapse of analgesia. We hypothesized that this was
due to KCC2 hypofunction resulting from nerve injury. Indeed,
the ensuing impaired Cl− extrusion capacity of the cells renders
them prone to a collapse of the transmembrane Cl− gradient
upon strong Cl− load induced by enhanced GABAA receptor
activity26,27. To challenge this hypothesis, we tested the effect of
rescuing Cl− homeostasis with the KCC2-enhancer CLP25728
on the analgesic action of the benzodiazepine site ligand
L838,417. We found that combining CLP257 and L838,417
produced a synergistic analgesia and reversed the collapse of
analgesia observed with higher doses of the benzodiazepine.
These findings point to a novel therapeutic strategy for
treatment of neuropathic pain, by combined targeting of the
appropriate GABAAR subtypes and restoring Cl− homeostasis.
Results
To perform an unbiased quantitative analysis of the changes in
markers of GABAAR- and GlyR-containing synapses following
PNI, it was important to objectively define the territory in the
SDH that corresponded to the central projections of the lesioned
afferents. We used rats in which we performed a constriction
injury (cuff model) of the sciatic nerve, resulting in a progressive
decrease in paw withdrawal threshold down to <2 g between 14
and 28 days post-surgery (Fig. 1a). By this time point, a distinct
patch of loss in IB4 labeling was clearly identifiable in lamina II of
the SDH in the L4–L5 spinal segments ipsilateral to the nerve
lesion (Fig. 1b). We used the territory defined by this IB4 labeling
loss to delineate the core of the central projection of injured
afferents15,29 (Fig. 1b). In this territory, IB4 labeling was decreased
to 35.9 ± 1.9% of sham animal values (Fig. 1c). A total of 82 rats
were used for subsequent quantitative immunocytochemical
analyses of markers of GABAAR and GlyR synapses. The loss in
IB4-labeled non-peptidergic terminals was not associated with a
loss in calcitonin gene related peptide (CGRP)-immunoreactive
peptidergic terminals, making the non-peptidergic afferents a
better marker to define a lesion after PNI (Fig. 1d).
Decrease in number of inhibitory synapses after nerve injury.
To study the number of inhibitory synapses, we used a cluster
recognition algorithm20. Typical examples of this cluster detec-
tion procedure are presented in Fig. 1e. Using this approach, we
defined binary masks delineating clusters of staining representing
either pre- or postsynaptic protein aggregates (Fig. 1e). The global
immunostaining intensity levels of post- and presynaptic inhibi-
tory markers did not change (gephyrin, VGAT, GAD65 and
GAD67; Fig. 1f). However, even if the intensities of VGAT and
GAD65,67 were higher within their own mask (Fig. 1e, g), we
found a significant decrease in the number of varicosities for these
markers, indicating a reduction in the number of both inhibitory
synaptic terminals and postsynaptic densities (Fig. 1e, h). To test
whether these changes correspond to alterations in GABAA or
glycine synapses, we also quantified the number of clusters of the
α1, α2, α3 and β3 subunits of the GABAARs and the α1 GlyRs.
We found a significant decrease in the number of clusters of α2,
α3 and β3 GABAARs and of α1 GlyRs, but not of the α1
GABAARs (Fig. 1i). Taken together, these findings indicate a
decrease in the number of both synapses with GABAAR and GlyR
in the SDH after nerve injury.
GABAAR synaptic scaling and subunit switch. Given the loss in
afferent terminals in the SDH, the changes in GABAAR clusters
we observed are difficult to interpret because GABAARs are
located both on SDH neurons and on terminals of primary
afferents20,30,31. In contrast, we have previously shown that
gephyrin and GlyR clusters are not located on primary afferent
terminals20. Thus, we quantified the intensity of GABAAR and
GlyR immunostaining within gephyrin clusters (Fig. 2a, c). We
found that, globally, the levels of β2,3 GABAAR staining per
gephyrin cluster were significantly increased (P < 0.05 t-test with
Welch correction; Fig. 2b, c) whereas the intensity of the β3
GABAAR subunit staining within gephyrin clusters did not
change in PNI animals (Fig. 2c) suggesting a synaptic increase of
the β2 but not of the β3 GABAAR (Figs. 1i, 2c). The greatest
variation was measured for the GABAAR α2 subtype (241 ± 35%,
P < 0.01 t-test with Welch correction; Fig. 2c). In contrast, we did
not observe any significant changes in the α1 and α5 subunits of
GABAARs nor in α1 GlyR (P > 0.05 t-test with Welch correction;
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Fig. 1 Peripheral nerve injury (PNI) causes a loss of inhibitory synapses. a Time course of the change in paw withdrawal threshold (WD50) to
mechanical stimulation following PNI in contrast to sham operated rats (n= 36 rats, 18 shams and 18 PNIs). In this study, all sham or PNI rats were used
between day 14 and 28 post-surgery. b Loss of IB4(+) terminals in the ipsilateral SDH (arrow). c Quantification of the number of IB4(+) terminals in sham
and PNI rats (n= 82 rats, 40 shams and 42 PNIs). d Intensity profiles of IB4 and CGRP immunolabeling in the superficial ipsilateral SDH from PNI
rats. e Example confocal images of gephyrin and α2 GABAAR immunolabeling in the SDH to illustrate the binary mask segmentation of clusters (right
insets). f–h Quantification of: the overall mean pixel intensity f, the mean intensity per cluster g, and the number of clusters h for selected inhibitory
synaptic markers in the area defined by the loss of IB4 labeling in PNI rats and corresponding area in sham-operated rats (Fig. 1b, d). i Quantification of the
number of clusters for a subset of GABAA and glycine receptor subunits in the area defined for Fig. 1f-h. Inset: example immunolabeling in the region of
interest defined by the loss of IB4 labeling. IB4, isolectin B4; CGRP, calcitonin gene related protein; VGAT, Vesicular GABA Transporter. GAD65,67,
Glutamatic Acid Decarboxylases 65 and 67; WD50, 50% paw withdrawal threshold. Number in each bar represents the number of sham or PNI rats used.
Error bars in all panels represent S.E.M. (*P < 0.05; **P < 0.01; ***P < 0.001). Source data is available as a Source Data file.
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Fig. 2c). The same observations were made with other anti-
GABAAR antibodies raised in guinea pig32 (Supplementary
Fig. 1). The increase in β2 subunits in inhibitory postsynaptic
sites suggests a synaptic scaling33,34, whereby the number of
receptors per synapse was increased. The increase in α2 and
α3 subunit staining, together with no change in α1, points to a
switch in GABAAR composition at inhibitory postsynaptic sites.
To compare the immunocytochemical changes with alterations
in mRNA expression, we used RT-qPCR of SDHs (Fig. 2d) and
found that the expression of mRNA coding for the GABAAR
α2 subunit (Gabra2 mRNA) in PNI animals was significantly
greater than that in shams (276 ± 108%, P < 0.05 t-test with
Welch correction). Interestingly, with the same rats analyzed, no
significant change occurs for Gabra1 or Gabra3 mRNA, which
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are associated with the GABAAR α1 and α3 subunits, respectively.
Both Gphn mRNA transcripts, encoding the inhibitory post-
synaptic scaffolding protein, gephyrin, and gene SLC12A5
encoding KCC2 were significantly decreased to 52 ± 11% (P <
0.05 t-test with Welch correction) and 47 ± 6% (P < 0.01 t-test
with Welch correction), respectively; whereas in the same rat
samples, the expression of the NKCC1 gene (SLC12A2) did not
change significantly (82 ± 17%, P > 0.05 t-test with Welch
correction). The rate of TFRC mRNA, as a house-keeping gene
product, was also constant compared to other house-keeping
genes that are known to stay stable in the dorsal spinal cord after
PNI35 like ACTB, RPL13a and GAPDH (Fig. 2e). These results
indicate a loss of inhibitory synapse scaffolding protein expres-
sion together with changes in opposite directions for Gabra2 vs.
SLC12A5 gene expressions. The use of RT-qPCR to quantify the
number of Gabra2 mRNA copies did not reveal in which kinds of
neurons this up-regulation occurred. For this reason, we used the
RNAscope technique in combination with Neurotrace Nissl
staining to reveal inhibitory (SLC32A1) or excitatory (SLC17A6)
neurons (Fig. 2f and Supplementary Fig. 2, 3). The up-regulation
of Gabra2 expression occurred in both types of neurons: from
2.0 ± 0.2 to 3.3 ± 0.2 copy index in SLC32A1(+) neurons (P <
0.001 t-test with Welch correction) and from 3.1 ± 0.2 to 4.4 ± 0.2
copy index in SLC17A6 (+) neurons for sham vs. PNI,
respectively (P < 0.001 t-test with Welch correction; horizontal
green bars indicate median values for each violin plot in Fig. 2f).
To test for a change in GABAAR subunit stoichiometry after PNI,
we applied Spatial Intensity Distribution Analysis (SpIDA)36 to α1
and α2 GABAAR subunit staining within gephyrin clusters. SpIDA
was developed to detect oligomerization states from conventional
immunostaining in tissue samples. One of the strengths of SpIDA is
that it can be applied to subsets of pixels within single images, such
as, in this study, the binary masks defined by the gephyrin
staining36,37, allowing us to analyze subunit stoichiometry at
synapses. The analysis revealed an increase in GABAAR α1
monomers but a decrease in α1 dimers whereas both monomeric
and dimeric α2 GABAAR increased significantly (Fig. 2g). The total
number of subunit count (1 per monomer+ 2 per dimer) revealed
by SpIDA (Fig. 2h) was consistent with the immunostaining
intensity analysis within gephyrin clusters (Fig. 2c). The results are
consistent with both a scaling of GABAARs at synapses and an α1
to α2 GABAAR subunit switch (Fig. 2h, i).
To determine whether the enrichment in α2,3 GABAAR
subunits had an effect on the kinetics of postsynaptic GABAAR
events, we recorded miniature (TTX-resistant) GABAA IPSCs in
SDH neurons. We found that the decay kinetics of GABAA
mIPSCs were significantly slower while their amplitudes were
unchanged (P < 0.05 Mann-Whitney U-test; Fig. 2j). These
modifications in mIPSC decay kinetics are consistent with
reported kinetics for α1 vs. α2,3 GABAAR subtypes38. Yet, the
known lower affinity for GABA of the α2,3 GABAAR subunits
compared to that of the α1 GABAAR39 (Fig. 2k) can explain why
the prolongation in GABAA mIPSCs decay time constant did not
yield higher peak amplitudes for these synaptic events, consistent
with previous reports for GABAAR38 or GlyR-mediated
mIPSCs40. Indeed, the lower affinity subunits yield slower on-
rate kinetics, resulting in lower peak channel open probability39,41
(see simulations in Fig. 2l).
KCC2 hypofunction does not explain changes in GABAAR
expression. We previously reported a down-regulation of KCC2
in SDH neurons following PNI using an immunoblotting
approach3. Here, we compared KCC2 immunostaining intensities
in sham vs. PNI rats (Fig. 3a–c). Following PNI, KCC2 was
downregulated by >75% compared to sham (Fig. 3c). We also
measured the distribution of KCC2 immunostaining around the
area defined by loss in IB4 labeling. Given that KCC2 is not
expressed in primary afferents3,20, the loss of IB4 does not bias
KCC2 quantification. Focusing on this region, however, provides
a common reference across sections allowing us to establish more
precisely the spatial relationship between KCC2 loss and the
region of the SDH where alterations in inhibitory synaptic mar-
kers were quantified (Fig. 3b–d and Supplementary Fig. 4). This
raised the question of whether the loss in KCC2 may lead to the
altered GABAAR expression we observed, as a relationship
between the two has been suggested to occur through Cl−
itself42,43. To test this hypothesis, we blocked KCC2 in spinal
cord slices of control rats with a selective KCC2 antagonist
(VU0240551)28,44–46 and we assessed Cl− extrusion capacity by
measuring EGABA under an imposed intracellular Cl− load (29
mM), as described in Ferrini et al.47. Under these conditions, the
measured experimental value for EGABA was more hyperpolarized
than the expected value, as calculated by Goldman-Hodgkin-Katz
equation (−44.1 ± 1.7 mV vs. −37 mV, respectively). Acute
administration of VU0240551 induced a significant depolariza-
tion of EGABA near to the expected value (−36.1 ± 1.0 mV; P <
0.001 paired t-test; Fig. 3e, f), indicating a complete block of Cl−
extrusion capacity. Despite the depolarizing shift in EGABA caused
by blocking KCC2, no changes in inhibitory postsynaptic markers
Fig. 2 Postsynaptic scaling and GABAAR subunit switch after peripheral nerve injury (PNI). a Illustration of the approach used to analyze
immunostaining at gephyrin(+) postsynaptic sites, from left to right: gephyrin immunostaining; its binarization (gephyrin mask); β2,3 GABAAR
immunostaining in gray scale; the product of the gephyrin mask with the image of the β2,3 GABAAR immunostaining allowing the quantification of intensity
of immunolabelled GABAARs specifically at inhibitory postsynaptic sites. b Profile plot examples of the β2,3 GABAAR immunolabelling intensity in sham vs.
PNI animals. c Bar graph summarizing the results obtained for GABAAR and α1 GlyR subunits at synapses defined by gephyrin. d qRT-PCR in the ipsilateral
SDH of Gabra1, Gabra2, Gabra3, GPHN (gephyrin), SLC12A5 (KCC2) and SLC12A2 (NKCC1) mRNAs in shams vs. PNIs. e The house-keeping gene TFRC
compared to three other house-keeping genes known to be stable after PNI (ACTB, RPL13a and GAPDH). f Violin plot of Gabra2 mRNA copy index detected
by RNAscope in 5 μm-thick z-stack spinal cord sections, in inhibitory SLC32A1(+) and excitatory SLC17A6(+) neurons of sham and PNI rats. g Spatial
Intensity distribution analysis (SpIDA) of the α1 and α2 GABAAR monomers or dimers within gephyrin clusters in sham vs. PNI rats. h Total number of the
α1 and α2 GABAARs (-mers) in shams vs. PNIs. i Schematic representation of the distribution of oligomerization states for these two subunits in sham vs.
PNI rats. j Quantitative analysis of the decay time-constant (τD) and amplitude of GABAAR mIPSCs in sham vs. PNI rats. Insets: representative
electrophysiological traces of GABAA mIPSC recordings along with superimposed averaged traces (of the 100 first detected mIPSCs). k Computer
simulations showing the fraction of open GABAA channels as a function of GABA concentration in the synaptic cleft in sham and PNI rats. For comparison,
these relations for pure α1β3γ2 (blue) and α2β3γ2 (orange) GABAAR stoichiometries39, 41 are also shown. As illustrated by the orange arrows, α2β2γ2
channels are supposed to have slower kinetics than α2β3γ2 channel41. l Computer simulations of Cl− conductance during a synaptic event in sham (black)
and PNI (red) rats as well as with the assumption of a conductance increase without a change in affinity (i.e., no synaptic switch in GABAAR subunit
stoichiometry modifying the affinity for GABA, dashed purple line). i.u., intensity unit. (*P < 0.05; **P < 0.01; ***P < 0.001). Source data is available as a
Source Data file.
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Fig. 3 Replication of the GABAAR subunit switch through BDNF-TrkB signaling, but not by blocking KCC2. a Low magnification confocal acquisitions of
IB4 and KCC2 immunostainings in sham SDH and their intensity profiles in the SDH b id. in PNI rats. c From left to right, averaged pixel KCC2
immunostaining intensities in the SDH of the L4-L5 lumbar segments of: ipsilateral SDH of shams, contralateral SDH of PNIs, in the surrounding (´out´)
and exactly in the region defined by the loss in IB4 labeling that delineates the core of the central projection of lesioned afferents in PNI rats (´in´).
d Parallel intensity quantifications of the IB4 and KCC2 immunostaining in the SDH of PNI rats in the same two last regions defined by the loss of IB4
terminals (outside vs. inside). e Currents evoked by muscimol puffs in dorsal horn neurons from control rats or in presence of the KCC2 antagonist
(VU0240551 at 15 µM) applied at increasing 12.5 mV voltage steps ranging from −93 to −18 mV. In red the muscimol response recorded at –43mV.
f EGABA recorded from superficial dorsal horn neurons of naive rats in control and in the presence of VU0240551 (-44.1 ± 1.7 mV, CTL; -36.1 ± 1 mV, VU;
n= 6 cells). g Antagonizing KCC2 did not modify the synaptic location at inhibitory sites of GABAARs and GlyRs. h Blocking KCC2 did not affect the
number of clusters of the α1, α2 or β2,3 GABAAR nor of the α1 GlyR or gephyrin. i Example of the synaptic α2 GABAAR expression increase in control spinal
cord slices incubated in 50 ng·ml-1 BDNF in artificial cerebrospinal fluid (ACSF) for 3 h. j The quantification of the synaptic GABAAR subunits showed an
increase in synaptic α2, α3 and β2,3 GABAAR subunits in BDNF-treated slices. The synaptic expressions in α1, α5 GABAAR and α1 GlyR remained
unchanged with BDNF treatment. k BDNF however did not modify the number of inhibitory synapses by itself. l Examples of GABAA mIPSC traces recorded
from control lumbar spinal cord slices incubated in ACSF with or without BDNF and averaged mIPSC aligned by rise time and y-scaled by amplitude. The
incubation in a BDNF-containing ACSF significantly prolonged the decay time of the GABAA mIPSC currents in dorsal horn neurons but did not significantly
modify their mean amplitude. m Blocking BDNF-TrkB signaling with an anti-TrkB antibody in PNI spinal cord paired-sections (2 μg ml−1 in ACSF for 3 h)
was able to reverse the GABAAR synaptic over-expression and phenotypic switch in PNI rats, n but did not modify the number in GABAAR, GlyR or
gephyrin clusters. Numbers of rats are indicated at the bottom of each bar; CTL, control rat. (*P < 0.05; **P < 0.01; ***P < 0.001). Source data is available as
a Source Data file.
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were observed. The rate of GABAARs and GlyR synaptic location
(Fig. 3g) and their number of clusters (Fig. 3h) in the SDH
remained stable in VU0240551 treated slices. This observation
leads to the conclusion that the change in inhibitory markers after
nerve injury is not secondary to KCC2 down-regulation.
The switch in GABAAR subunit composition is BDNF-
dependent. After PNI, activation of spinal microglial P2X4Rs
evokes the release of BDNF48,49 which is known to down-regulate
neuronal KCC2 expression50–54. To test whether BDNF was also
involved in the GABAAR subunit switch, we incubated slices from
control animals for 3 h with BDNF (Fig. 3i). We found an increase
in the intensity of the α2,3 (P < 0.05 t-test with Welch correction)
and β2 GABAARs (P < 0.01 t-test with Welch correction), but not
in α1,5 GABAARs nor in α1 GlyRs at synapses (Fig. 3j). These
changes reproduce those found after nerve injury (Fig. 2c). In
contrast to PNI animals, however, we observed no significant
changes in number of clusters for any of the subunits (P > 0.05 t-
test with Welch correction; Fig. 3k). These results indicate that
BDNF is sufficient to replicate the subunit switch, but not the
change in number of synapses. These observations indicate that
the postsynaptic GABAAR subunit configuration (e.g., scaling and
subunit switch) and the number of inhibitory synapses are regu-
lated by distinct mechanisms.
Consistent with our electrophysiological results in PNI animals
(Fig. 2j), incubating spinal slices with BDNF caused a significant
prolongation of GABAAR mIPSCs without affecting their
amplitude (controls τD= 16.1 ± 1.3 ms, BDNF τD= 28.2 ± 4.0
ms, P < 0.05 Wilcoxon matched-pairs signed rank test; Fig. 3l). As
previously noted, this finding is consistent with the slower
kinetics associated with α2,3 and β2 GABAAR subunits23,38,55,56.
Taken together, our findings indicate that, in addition to a
reduced KCC2 expression3 due to TrkB activation in neuropathic
animals49, GABAARs themselves undergo important modifica-
tions with a subunit switch and an enrichment in α2,3 and β2
GABAARs at inhibitory postsynaptic sites with BDNF (Fig. 3i–k).
As shown above, blocking KCC2 alone is not sufficient to
generate this synaptic up-regulation in specific GABAAR
subtypes, indicating that the change in GABAAR expression is
not secondary to TrkB-induced KCC2 downregulation. Our
results thus suggest that GABAARs and KCC2 may be both
regulated by TrkB signaling. We therefore tested whether
blocking TrkB in PNI animals could restore the original GABAAR
subunit composition. Incubating spinal slices from PNI animals
with a function-blocking anti-TrkB antibody49,57 caused an
inverse change in GABAAR subunit expression to that of BDNF
applied to control slices (Fig. 3m), without significantly affecting
the number of clusters for each of the synaptic markers (Fig. 3n).
In conclusion, BDNF-TrkB signaling appears necessary and
sufficient to explain the signature of change in postsynaptic
GABAAR composition after nerve injury.
BDNF-induced GABAAR modulation is Ca2+-dependent. As
Ca2+ has been shown to modulate GABAARs58–61, we investi-
gated the Ca2+-dependence of the effects of BDNF and PNI. For
this, we used the faster and slower Ca2+ chelators BAPTA and
EGTA, respectively62,63 (Supplementary Fig. 6a). In control ani-
mals, no significant difference was observed in decay times
between BAPTA and EGTA (BAPTA τD= 21 ± 2.6 ms, EGTA
τD= 16.1 ± 1.3 ms, P > 0.05 Mann-Whitney U-test; Supplemen-
tary Fig. 6b) but in presence of BDNF, GABAA mIPSC decays
were significantly faster with BAPTA (τD= 16.7 ± 1.8 ms) vs.
EGTA incubations (τD= 28.2 ± 4 ms, P < 0.05 Mann-Whitney
U-test; Supplementary Fig. 6a). BAPTA abolished the differences
in mIPSC decay time constant between controls, BDNF-
incubated and PNI rat spinal slices (controls, τD= 21 ± 2.66 ms,
BDNF, τD= 16.7 ± 1.8 ms, PNI, τD= 17 ± 1.4 ms, P > 0.05 Mann-
Whitney U-test; Supplementary Fig. 6b). In contrast to BAPTA,
EGTA is incapable of clamping certain fast Ca2+ fluctuations64.
Fast intracellular Ca2+ transients thus appear necessary for the
GABAAR subunit switch.
L838,417 is analgesic in PNI rats but not in shams. Anti-
hyperalgesia by α2 GABAAR has been shown to preferentially
occur via a spinal site of action and not through supraspinal
sites65. We have shown here that the α2,3 GABAARs were up-
regulated in the SDH of PNI animals. To test whether
the GABAAR α2,3 subunit-preferring benzodiazepine L838,417
was more effective in PNI than in sham animals, we injected
3.3 mg kg−1, intraperitoneal (IP) of L838,41725,66. Rats were
tested for mechanical sensitivity every hour for four hours after IP
injection of L838,417 (Fig. 4a). In shams, the mechanical with-
drawal threshold (WD50) was not significantly affected by
L838,417 (P > 0.05; paired t-test Fig. 4b) whereas in PNIs, it was
significantly increased (P < 0.001 paired t-test; Fig. 4b). The
relative improvement in WD50 between sham and PNI rats was
significantly different (P < 0.001 one sample t-test; Fig. 4c). We
conclude that L838,417 had a significant effect on mechanical
WD50 in PNI animals only, consistent with the switch to α2,3
GABAARs (Fig. 2c,g).
Dose-response profile of L838,417 and CLP257 analgesia. The
strength of GABAAR-mediated transmission can be significantly
impaired by a loss of KCC2 and ensuing degradation in trans-
membrane Cl− gradient67,68. Furthermore, the efficacy of
enhancing GABAA-mediated inhibition with a benzodiazepine
may be limited in conditions of impaired Cl− extrusion, because
of the inability of the cells to cope with the Cl− load27. This
prompted the hypothesis that enhancing Cl− extrusion by
increasing KCC2 activity may potentiate benzodiazepine analge-
sia. To test for a synergistic effect of tapping into these two
effector mechanisms, we first built dose response curves for
analgesia by L838,417 and the KCC2 enhancer CLP25728
(Fig. 4d–g). For L838,417, the EC50 and the maximum possible
analgesia (MPA) derived from fitting the Hill equation (Eq. 2) to
the data were 0.43 ± 0.23 mg kg−1 and 31.2 ± 4.4%, respectively
(Fig. 4e). The response at 20 mg kg−1 (in gray) was not included
in the fit because this point was significantly lower from MPA
achieved at 3.3 mg kg−1 (P < 0.05 paired t-test; Fig. 4e). This
collapse in analgesia at 20 mg kg−1 of L838,417, as reported for
other benzodiazepines69, may result from a collapse in Cl− gra-
dient. Computer simulations predict that such a collapse arises
from high Cl− load (from high GABAAR conductance; ginh)
combined with impaired Cl− extrusion capacity (Fig. 4e, inset
and methods). Dose response analysis for CLP257 revealed an
EC50 of 29.4 ± 4.2 mg kg−1 and MPA of 22.9 ± 1.3% without any
collapse in analgesia at high doses (>3× the dose required to reach
saturation) in contrast to L838,417 (Fig. 4f, g). To estimate the
tissue concentration of CLP257, we analyzed by LC/MS (liquid
chromatography/mass spectrometry) the concentration of
CLP257 in the CNS at different time points after 100 mg kg−1 i.p.
injections in vivo. We found that the concentration of CLP257 in
brain homogenates was less than 0.2 µM when measured 30 min
after i.p. injection and dropped to less than 0.06 µM after 1 h.
Thus, the effective concentration at the target site in the
spinal cord was in the sub-micromolar range. This indicates
a submaximal dose for KCC2 activation at the target site, con-
sistent with the poor pharmacokinetic profile of CLP25728
(Supplementary Fig. 7).
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CLP257 enhances membrane expression of KCC2 in PNI
animals. Previous reports have shown that CLP257 acts by
enhancing membrane expression of KCC2 in different
paradigms28,70,71. To confirm this effect in our paradigm, we
performed two types of quantitative immunocytochemical ana-
lyses. First, we analyzed intensity profiles from hundreds of
individual neuronal cell bodies (definable by continuous mem-
brane across the entire circumference) in spinal sections taken
from sham and PNI rats, and immunostained for KCC2 (Fig. 5a).
We found that KCC2 profiles displayed an important decrease
specifically at the cell membrane in PNIs compared to shams
(Fig. 5a, b). In PNI CLP257-treated rats (40 mg kg−1), we
observed an increase in KCC2 levels at the membrane compared
to PNI vehicle injected animals (Fig. 5c, d). Second, to obtain a
global index of KCC2 expression at the membrane in both neu-
ronal cell bodies and dendrites, we subtracted the mean pixel
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Fig. 4 Pharmacological characterization of L838,417- and CLP257-induced analgesia. a Variations in mechanical WD50 thresholds over 4 h after IP
injection of L838,417 (3.3 mg kg−1) in sham and PNI rats, 14–28 day post-surgery. b Mechanical WD50 thresholds were measured −1 h/+ 1 h of L838,417
injection in shams and in PNIs. c Percentages of change between the two time points in shams vs. PNIs. d Partial reversal of mechanical allodynia by
different doses of IP injected L838,417 in PNI rats. Animals were tested every hour and followed for 4 h. e Dose-response curve of L838,417 in Fig. 4d and
fit curve by the Hill equation with variable slope (Eq. 2 in methods; note that the 20mg kg−1 data point was ignored in the fit as the value was significantly
lower than the one at 3.3 mg kg−1; P < 0.05 paired t-test). Computer simulations (Inset) showing a collapse of net hyperpolarizing anionic current when the
inhibitory conductance (ginh) is increased beyond an optimal point. f Partial reversal of mechanical allodynia by increasing doses of IP injected KCC2
enhancer, CLP257 in PNI rats. g Dose-response curve of CLP257 in Fig. 4f and fit curve by the Hill equation with variable slope (Eq. 2 in methods). (*P <
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intensity in the intracellular compartment (computed from a
number of well-defined intracellular areas) from the mean pixel
intensity across the entire image area as previously described71
(Fig. 5e). This global analytic method revealed a decrease of
KCC2 immunostaining to 25.1 ± 6.5% of sham values in PNI
animals (P < 0.01, t-test with Welch correction; Fig. 5f). The
average intensity per pixel in the intracellular space (normalized
to membrane intensity in sham rats) did also significantly
decrease in PNI animals (46.9 ± 8.4% in shams rats vs. 17.8 ±
4.3% in PNI rats; P < 0.05 t-test with Welch correction; Fig. 5f).
We found that two hours after 40 mg kg−1 CLP257 treatment in
PNI rats, the membrane KCC2 levels increased to 137.9 ± 10.1%
of sham values (P < 0.01 t-test with Welch correction; Fig. 5g). In
contrast, the average pixel intensity in the intracellular com-
partment remained stable in both vehicle and CLP257-treated
PNI animals (vehicle 70 ± 9.8% vs. 66.6 ± 6.8% with CLP257,
c
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Fig. 5 CLP257 enhances KCC2 membrane expression in rats with peripheral nerve injury (PNI). a Confocal laser scanning microscopy (CLSM) images
showing KCC2 immunostaining in PNI vs. sham animals. Insets show examples of KCC2 profiles of magnified neurons within these two confocal
acquisitions (Y-scale bar= 500 i.u.; horizontal dashed lines are 3 pixel-thick and correspond to a selected KCC2 profile and the intensity axis origin).
b Averaged intensity KCC2 profiles of visually identified sham and PNI neurons across their plasma membrane. Sham (Cyan) n= 77 neurons in 8 rats; PNI
(red) n= 190 neurons in 8 rats. c CLSM images of KCC2 immunostaining in PNI vehicle vs. PNI CLP257 i.t. injected rats. Insets show examples of KCC2
profiles of magnified neurons within these two confocal acquisitions. d Averaged intensity KCC2 profiles in PNI+ vehicle (red) n= 268 neurons in 12 rats
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Source Data file.
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P > 0.05 t-test with Welch correction; Fig. 5g). These results
indicated that CLP257 restores a significant proportion of KCC2
at the neuronal membrane after PNI. Ultrastructural immunos-
taining for KCC2 using the same antibody, illustrates the dis-
tribution of KCC2 in different subcellular compartments in
neurons (Fig. 5h–j).
L838,417/CLP257 act synergistically to produce analgesia. Our
working hypothesis for the paradoxical decrease in analgesia at
high dose with the L838,417 in PNI rats is that enhancement of
GABAAR function caused a collapse of the Cl− gradient due to
KCC2 hypofunction (Fig. 4e). Given that CLP257 enhanced KCC2
membrane expression (Fig. 5), we sought to test whether combi-
nation of the two drugs would improve analgesia. We adminis-
tered, in a single bolus, a mixture of L838,417 and CLP257 at a
fixed ratio that takes into account the relative affinities of the two
drugs (Fig. 4e, g). The experimental mixture of the two compound
doses (A50) that produces half of the maximal MPA (Fig. 6b) was
significantly lower than the expected concentration calculated
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distance run with the same drugs as in i, 2 h after i.p. injection. (*P < 0.05; **P < 0.01). Source data is available as a Source Data file.
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using the isobologram (P < 0.05 t-test with Welch correction;
Fig. 6a–c). This implies that combined doses of L838,417 and
CLP257 act synergistically for an increased effect when given
simultaneously. Assuming that the analgesic effect of the two
drugs is due to their impact on anion current (i.e., the sum of the
hyperpolarising Cl− current and the depolarizing HCO3− current
through GABAA channels), we performed two computer simula-
tions to test whether the observed synergistic effect can be
explained by the interactions between Cl− extrusion through
KCC2, Cl− influx through GABAARs and net anion current. We
first simulated the effects of L838,417 and CLP257 separately and
convoluted them to obtain an additive effect as if the they were
acting on a common effector (Fig. 6d). But, if we consider that the
two drugs act on different mechanisms, L838,417 on the anionic
inhibitory conductance (ginh) and CLP257 on the Cl− extrusion
capacity (UKCC2), they can theoretically act synergistically to
increase the Cl− current through anion permeable channels. This
would allow overcoming the upper-limit obtained by the use of a
single drug or by their additive effect on a common effector
(Fig. 6e). Figure 6f overlays experimental data of MPA measure-
ments of drug combinations as in Fig. 6a, b, and of L838,417 with
a saturating dose of CLP257 (100mg kg−1) with the expected
additive effect based on data obtained from individual dose-
response curves (Fig. 4e, g)72–74. It shows that drug combinations
yielded higher analgesia than expected from mere additive action
via a common effector (Fig. 6f). Saturating doses of both drugs
produced greater analgesia than that obtained by each compound
individually (Fig. 6g). Furthermore, the addition of CLP257 pre-
vented the collapse of analgesia observed at high doses of
L838,417, consistent with improved Cl− homeostasis by KCC2
enhancement (Fig. 6f, g).
To complement our results using the nociceptive reflex
response to von Frey stimulation, we used an assay involving a
more complex behavioral response75. The application of liquid
nitrogen with a cotton tip to the hindpaw was used to evoke a
combination of prolonged lifting, licking, and shaking behaviors.
We similarly found a synergistic effect of combining L838,417
and CLP257 in this assay (Supplementary Fig. 8).
It has been proposed that a significant advantage of using the
α2,3-preferring L838,417 is that it can produce analgesia without
sedation25. We found that CLP257 also does not produce motor
side effects (Fig. 6h)28. Interestingly, potentiating the action of
L838,417 with CLP257 did not induce significant motor
impairment at doses that yielded equivalent analgesia to that of
gabapentin but which was in contrast affecting time spent on
rotarod (Fig. 6i, j)28.
Finally, we tested the capacity of SDH neurons to maintain their
Cl− gradient in PNI animals in condition of Cl− load imposed by
repetitive GABAAR-mediated synaptic input (Fig. 7). To achieve
this, we used repetitive electrical stimulations (Fig. 7a) to evoke
monosynaptic inhibitory postsynaptic currents (eIPSCs) in the
presence of glutamate receptors blockers. When holding the cells
at 0 mV, and delivering a train of 25 pulses at a frequency of
20 Hz, we observed a collapse in amplitude of the eIPSCs as
previously described47,76,77. We observed a stronger collapse of
eIPSCs in the presence of the benzodiazepine site ligand L838,417
as expected from the enhanced Cl− load produced by potentiation
of GABAAR function (enhanced amplitude and decay kinetics;
thus, enhanced charge transfer; Fig. 7b). Since CLP257 increases
the Cl− extrusion capacity of the cells, the collapse in eIPSC was
significantly reduced when the benzodiazepine was applied in
conjunction with either steady-state of 5 μM or within 15min of
100 μM CLP257 (P < 0.05 Wilcoxon matched-pairs signed rank
test; Fig. 7c, d). Importantly, adding CLP257 did not affect the
properties (peak and decay) of low frequency eIPSCs (not shown)
nor of the first eIPSCs at the beginning of each train (Fig. 7b),
indicating that the reversal of the collapse was not due to an effect
on GABAAR function, but was rather due to an effect on Cl−
extrusion capacity (Fig. 7a, b). Consistent with this, such a reversal
of eIPSC collapse in amplitude was not observed at a holding
potential of−90 mV, when the GABAA currents are dominated by
HCO3− anions (Fig. 7e, f). Because maintenance of HCO3−
gradient in the cells is virtually instantaneous compared to the rate
of Cl− regulation by the membrane transporter KCC2, the decline
in eIPSC at −90 mV mostly reflects changes in GABA release or
GABAA receptor desensitization rather than ionic plasticity78,79.
The lack of effect of CLP257 on the decline of inward HCO3−-
mediated eIPSC amplitude therefore indicates that it had no effect
on GABAA receptors nor transmitter release, consistent with
selective action of the compound on Cl− extrusion capacity. These
results thus confirmed the postulate made above that CLP257
prevents the Cl− overload and ensuing collapse of inhibition
caused by L838,417.
The dual advantage of enhancing KCC2 for improved analge-
sia. To further validate the postulate that the narrow therapeutic
window of L838,417 is due to a collapse in the transmembrane
Cl− gradient, we first conducted computer simulations using a
one compartment neuron model which takes into account Cl−
accumulation and extrusion through KCC226,27. We found that
increasing only the inhibitory anionic conductance (ginh) yielded
a collapse in net inhibition when ginh is so large that Cl− influx
overwhelms the Cl− transmembrane gradient. Increasing in the
rate of Cl− extrusion by 40% was sufficient to prevent the collapse
(Fig. 8a). Forty percent of Cl− extrusion improvement is con-
sistent with the value of increase in KCC2 membrane expression
produced by 40 mg kg−1 of CLP257 treatment (Fig. 5, c, d and g).
These results indicate that a deficit in Cl− extrusion can explain
the collapse in analgesia at high doses of L838,417 (Fig. 4e). This
suggests that the L838,417 dose-response curve is the result of two
independent processes. To test this, we modeled a L838,417 dose-
response curve as the product of two functions: a normal dose-
response curve without collapse (with maximum obtained from
Fig. 6g) and an inverse normalized dose-response curve repre-
senting the collapse (Fig. 8b). This product of two functions
(Eq. 4) dramatically improved the fit quality of the original data
set over the fit assuming a single monotonic process (Fig. 8b).
These results indicate that combining CLP257 with L838,417 has
the dual benefit of pharmacological synergy and extending the
therapeutic window of efficacy of the benzodiazepine. Figure 8c
summarizes schematically the beneficial effect of the synergistic
interaction between a Cl− extrusion enhancer and a GABAAR
positive modulator.
Discussion
Loss of inhibition, or disinhibition, at the spinal level has long been
hypothesized as underlying hypersensitivity in neuropathic pain.
Yet, how GABAA and glycine receptor-mediated inhibition is
modified has remained elusive. Previous studies13–15 have reported
a selective loss in inhibitory GAD-positive terminals in the SDH
after nerve injury. It remained uncertain, however, whether this
reflected mainly a loss of postsynaptic inhibitory connections. This
is because the terminals of sensory afferents, which are important
targets of GABAergic inhibition, undergo significant attrition at
the spinal level following PNI29,80. Here, taking advantage of our
previous demonstration that gephyrin clusters are exclusively
found on SDH neurons and not on primary sensory terminals20,
we specifically interrogated the postsynaptic component. We
found a selective loss in inhibitory postsynaptic sites (attested
by the reduction in gephyrin clusters)40, concurrent to the decrease
in number of GAD-positive terminals. Unexpectedly, however,
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the loss of connection was associated with an overall increase
in GABAARs at the remaining synapses (synaptic scaling) and a
phenotypic switch towards the α2,3 subunits on the SDH
neurons. In contrast, synaptic α1,5 subunits of the GABAARs and
α1 GlyRs were statistically unchanged. This observation is con-
sistent with previous findings81 of a greater plasticity at GABAAR
than GlyR at inhibitory synapses82. The stoichiometry SpIDA
analysis in α1 and α2 GABAAR subunit oligomerization83 dis-
played a synaptic switch towards α2 monomer and α2 dimer
enrichment, reinforcing the importance of the α2 GABAAR sub-
type in PNI animals and participating to its ability to reverse
pathological pain25.
It is interesting to note that TrkB signaling appears common to
both the loss of KCC248,50,51,53,54 as well as to the synaptic scaling
at GABAA synapses and subunit switch, yet the changes in
GABAAR were not secondary to loss of KCC2. We also found
that the GABAAR plasticity was Ca2+ dependent. This may
explain the fact that previous reports failed to see certain changes
in GABAAR mIPSC kinetics after PNI when recording with low
intracellular pipette Ca2+ concentration or strong Ca2+ buffering
conditions13,84.
The switch in subunit composition toward α2,3 and β2 is
consistent with slower decay kinetics of GABAAR mIPSCs39,41.
Switching from α2,3 to α1 GABAAR composition appears to be a
typical change that occurs in several systems during
development85,86. During the same time period, the β subunits
switch from β2 to β3 GABAAR in the spinal cord86. These
changes in α and β subunits underlie differences in decay kinetics
of synaptic events38. The net result is a difference in charge
carried, and hence Cl− load. Here, the loss of SDH KCC2 after
nerve injury, concurrent to an increase Cl− charge carried by
GABAARs, raises the intriguing question of the net functional
impact of these two opposed phenomena. For example, the
resulting apparent increase in GABAAR tone after nerve injury
may be defeated by the loss of KCC2 after nerve injury. The
consequent greater Cl− load may in fact be counterproductive
and lead to a more dramatic collapse of inhibition27. Yet,
the subunit switch we observed provides a substrate for the
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Fig. 7 CLP257 protects from dynamic collapse in Cl− gradient under a barrage of inhibitory inputs. a Three representative traces of repetitive inhibitory
stimulation (20 Hz, 25 stimulations) at 0 mV in PNI, with ACSF (gray trace), with L838,417 (2 µM, black trace) applied in the bath or with L838,417 and
CLP257 (100 µM, red trace) of transversal spinal cord sections. The depression of eIPSCs at 0mV was amplified by L838,417 in PNI due to Cl−
accumulation and can be reversed by CLP257. Stimulus artefacts have been canceled. b Representative traces showing the increase in amplitudes and
decay times with L838,417 with or without CLP257 vs. ACSF on averaged eIPSCs evoked at 1 Hz. Inset shows the sames traces scaled to peak for kinetics
comparison. c Averaged eIPSC amplitude depression at 0mV during the repetitive inhibitory stimulation protocol in two pharmacological conditions:
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analgesic efficacy of α2,3 preferring benzodiazepines after nerve
injury25,66, indicating that, in fact, sufficient residual effective
GABAA inhibition remains after nerve injury to achieve analgesia,
despite the loss of KCC2. It also explains the negligible con-
tribution of α1 GABAAR to analgesia after nerve injury25.
The MPA achieved in our study was at most 50% when
combining both L838,417 and CLP257. This contrasts with the
MPA reported by Knabl et al., reaching virtually 100% using
L838,417 alone25. We hypothesized that the difference between
our two studies lies in the fact that the level of hyperalgesia
achieved in our model was much greater than in Knabl et al. We
used a model with higher starting hyperalgesia to better resolve
synergism. To test our hypothesis, we conducted an additional set
of experiments using larger polyethylene tubing, yielding a WD50
of ∼5 g (in contrast to the WD50 of <2 g normally reached in our
study). Under these conditions, a dose of 3.3 mg kg−1 of L838,417
was sufficient to produce ∼100% MPA, confirming our assertion
(Supplementary Fig. 9).
The hypothesis of synergism between enhancing GABAAR
function together with Cl− extrusion holds for postsynaptic
inhibition because KCC2 is CNS-specific, i.e., on dorsal horn
neurons3,19, not primary afferents. Yet, a good part of GABAAR-
mediated inhibition in the spinal cord is presynaptic and occurs
onto terminals of primary afferents themselves20,27,30,87. Inter-
estingly, while this presynaptic inhibition appears to participate in
GABAA-mediated analgesia in inflammatory conditions31, only
postsynaptic GABAARs appear to be involved in analgesia fol-
lowing nerve injury31. The latter is consistent with previous
observations of a loss of IB4+ terminals in the SDH after nerve
injury, indicating that presynaptic contribution is likely
minimal29,88. It is also consistent with our finding of an increase
in α2,3 GABAAR subunits in postsynaptic sites of dorsal horn
neurons after PNI.
It remains that the loss of KCC2 significantly mitigates the
efficacy of GABAA enhancing drugs. A prediction from this is
that drugs counteracting the depolarization of EGABA subsequent
to increased Cl− influx can enhance the analgesic efficacy of
benzodiazepines. Consistent with this was the demonstration that
the carbonic anhydrase inhibitor acetazolamide, which causes a
collapse of the depolarizing HCO3−, enhanced the analgesic
efficacy of midazolam69. The strategy remains limited however
because it does not counteract the deleterious effect of the
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Fig. 8 Dual advantage of enhancing KCC2: L838,417 potency and efficacy improvement. a Computer simulations predicting a collapse in anionic current
when inhibitory conductance (ginh) is increased beyond an optimal value (black curve, see methods). When an increase of 40% in the strength of Cl−
extrusion through KCC2 was simulated, the collapse in anionic current for large inhibitory conductance was prevented (red curve as in Fig. 4e).
b Experimental MPA (maximum possible analgesia) with L838,417 (black empty dots) was fitted with a Hill equation (black curve) where the last data
point was ignored (which correspond to a decline in analgesia). To better describe the collapse in inhibition occurring at high L838,417 doses, two
independent processes were combined to generate the final fitting function. The fitting function (purple curve, Eq. 4) that takes into account the collapse
consists of the product of a normal dose-response curve (Eq. 2) without collapse (dashed red curve with amplitude set to the value obtained in Fig. 6g) and
an inverse normalized dose-response curve representing the collapse (dashed blue curve). Combining the two independent processes in a single fitting
function (purple curve) yielded a better global fit of the experimental MPA with L838,417 than a simple Hill fit (black curve). c A schematic representation
of how CLP257 and L838,417 synergistically act on net inhibition. L838,417 increases anionic conductance while CLP257 favors Cl− extrusion via KCC2.
This, in turns interacts to determine the value of Cl− reversal potential as well as the net anionic current which promotes analgesia155. F is the Faraday
constant, J denotes a flux and U is a proportionality constant capturing the strength of KCC2 activity (see Methods). Source data is available as a Source
Data file.
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collapse in Cl− gradient resulting from KCC2 hypofunction27. In
contrast, our results with CLP257 indicate that enhancing KCC2
can improve benzodiazepine-induced analgesia on a dual front:
enhancing their potency and extending their window of efficacy
by preventing their paradoxical loss of efficacy at high doses
(Fig. 8), consistent with earlier predictions28,45. Inhibiting
NKCC1, which normally imports Cl−, could appear as a potential
alternative to enhancing KCC2. However, the latter has the
advantage of offering i) a selective CNS target, avoiding side effect
liability of targeting NKCC1 and ii) enhancing Cl− extrusion,
thus directly counteracting Cl− load resulting from enhancing
GABAA function28. As KCC2 is absent from primary afferents
and their terminals3,20, the synergistic action between L838,417
and CLP257 selectively targets SDH neurons. Such KCC2-
enhancer in combination with the proper benzodiazepine can
be considered as a promising therapeutic combination. Despite
the poor pharmacokinetic profile of CLP257, it was possible to
significantly improve benzodiazepine-induced maximal analgesia.
This is promising for future, improved versions, of KCC2
enhancers. Our recent finding that microglia-BDNF maintains
KCC2 downregulation even at 3 months post-injury in rats
indicates that this therapeutic strategy may be relevant to long-
term chronic conditions89.
Methods
Animals. Adult male CD Sprague–Dawley rats, 2 months old at the time of the
beginning of the experiments, were used. Rats were housed under a 12 h:12 h light/
dark inverted cycle. All experimental procedures were performed in accordance
with guidelines from the Canadian Council on Animal Care and the International
Association for the Study of Pain.
PNI pain model and behavioral testings. PNI was induced by surgically placing a
polyethylene cuff (2 mm in length, inner diameter 0.76 mm, Intramedic PE-60,
VWR, Canada) around the sciatic nerve of adult rats as previously described3,49,90.
A second set of PNI rats for complementary experiments was done with PE-90 cuff
(inner diameter 0.86 mm, see Supplementary Fig. 9). Another group of rats
received sham surgery, in which the sciatic nerve was exposed but no cuff was
placed. The 50% paw withdrawal threshold (WD50) to mechanical stimulation was
assessed, as described3,28,45,49,91. Twelve von Frey filaments were used ranging
from size 2.44 (0.04 g) to size 5.88 (60 g) in order to adequately test sham as well as
lesioned rats (Bioseb Von Frey filament kit). When drugs were used, behavioral
baselines were determined just prior to drug single injection (t= 0 h ≡ predrug)
and then rats were blind-tested at 1 h, 2 h, 3 h and 4 h post-drug injection. The
experimenter was blind to drug and dose. Animals were sacrificed 3 weeks post-
PNI for tissue processing. Behavioral testing was done in a noise isolated and air
conditioned (22 °C) behavior room. The behavioral female92 experimenters were
wearing a 3M Versaflo TR-300-ECK suit and respirator kit.
As a supplement to simple nociceptive withdrawal reflexes, a more complex
behavioral test75 was added to the up-down Chaplan method91 described above.
Sterile cotton tipped applicators (Puritan; catalog #25-806-1PC) were dipped into
liquid nitrogen and then applied under the hindpaw of neuropathic nerve-injured
rats (tested between 14 and 28 days post-surgery). Note that one q-tip was used for
two liquid nitrogen applications only. For each rat, the test was repeated 5 times
spaced by 5 min intervals between each q-tip application and complex behavioral
response (E-score) was measured on a semi-quantitative scale of 10 as the sum the
5 successive responses rated as follow: 0= a rapid transient lifting, licking, or
shaking of the hindpaw, which subsides immediately; 1= lifting, licking, and/or
shaking of the hindpaw, which continues beyond the initial application, but
subsides within 5 s; 2= protracted, repeated lifting, licking, and/or shaking of the
hindpaw75. A baseline response evoked by liquid nitrogen application was obtained
one hour before drug i.p. injection. Evoked responses were then measured 2 h post-
drug injection. The experimenter was blind to drug and dose.
Tissue processing. Before tissue processing in PNI and sham rats, mechanical
WD50 thresholds were measured to confirm that PNIs were hypersentitive and that
shams were not. Rats were anesthetized with a mixture of ketamine/xylazine (0.875
and 0.125 mg kg−1) and quickly sacrificed by decapitation. A skin incision was
made along the back of the animal. A 10 ml syringe equipped with an 18 Gauge
needle was filled with cold PBS beforehand. The extraction consisted in inserting
the needle in the spinal canal at the L6-S1 level and then in ejecting the whole
spinal cord by a strong flow of cold PBS through the spinal canal. The spinal cord
extracted in this way was immediately frozen in powdered dry ice for one minute.
The L4–L5 spinal cord segments were separated from the whole spinal cord with a
cold razor blade. In order to keep the tissue frozen and to avoid any protein
denaturation, the spinal cord segments were manipulated with cold forceps on a
dish placed upside-down on dry ice. Then the L4–L5 spinal cord segments were
placed in pre-cooled 2 ml plastic tubes, which were stored in a −80 °C freezer until
further tissue processing. Transverse sections of 14 μm in thickness were cut from
the frozen spinal cord with a cryostat (Leica CM 3050S) and mounted onto gelatin-
subbed slides (Fisherbrand).
Immunocytochemistry. Sections were then immersed for 10 min in freshly depo-
lymerized 4% paraformaldehyde in 0.1M sodium phosphate-buffered (PB 0.1M;
pH 7.4) and rinsed in phosphate-buffered saline (PBS, 0.01M; 3 × 10min). Sections
were incubated for 12 h at 4 °C in primary antibody mixtures diluted in PBS con-
taining 4% normal donkey serum (Jackson Immunoresearch; catalog # 017-000-
121). Triton X-100 was never added to the solutions. After washing (4 × 5min), the
sections were immersed in a solution containing a mixture of the appropriate
fluorochrome-conjugated secondary antibodies diluted (1:500) in PBS (pH 7.4)
containing 4% normal donkey serum for 1.5 h, at room temperature. Sections were
rinsed in PBS (0.01M; 4 × 5min) and incubated in an anti-gephyrin-Oyster anti-
body and Isolectin-B4 (IB4) solution for 1.5 h (see below for antibody and lectin
details). Finally, sections were rinsed (4 × 5 min) and quickly immersed in distilled
water and cover-slipped using Aquapolymount (Polysciences). Note that for KCC2
immunostaining, rats were perfused transcardially with 4% paraformaldehyde in
0.1M phosphate buffer (pH 7.4) for 30min. Spinal cord segments L4–L5 were
collected, postfixed for 60 min in the same fixative, and cryoprotected in 30%
sucrose overnight at 4 °C.
Antibodies. The antibodies against the α-GABAAR subtypes used in this study
were bought from Synaptic Systems (Sysy) and raised in rabbit. A set of com-
plementary experiments using guinea pig anti-α1,2,3 GABAAR antibodies is illu-
strated in Supplementary Fig. 1, the antibodies were generously provided by
Dr. Jean-Marc Fritschy. All these primary polyclonal antibodies were raised against
synthetic peptide sequences derived from the GABAAR α1, α2, α3, α5 subunit
cDNAs and coupled to KLH93. Regarding the Sysy antibodies, the following rat
peptide sequences were used: α1 subunit residues 28–43, α2 subunit residues
29–37, α3 subunit residues 29–43, and α5 subunit residues 26–43. All these anti-
bodies were raised in rabbits. The dilutions of the antibodies were: Anti-GABAAR
α1 subunit 1:1000 (Sysy Catalog #224 203), α2 subunit 1:1000 (Sysy, Catalog #224
103), α3 subunit 1:1000 (Sysy, Catalog #224 303) and α5 subunit 1:1000 (Sysy,
Catalog #224 503). All these antibodies were affinity purified and their affinity has
been tested in rats (Sysy). The specificity of the Sysy anti-GABAAR antibodies has
been determined by Sysy by using mutant mice lacking the α1 and α2 subunit
genes. In our lab, we have tested the anti-α5 GABAAR subunit 1:1000 (Sysy,
Catalog #224 503) in Gabra5−/− transgenic mice and there was a complete absence
of GABAAR immunostaining in both spinal cord94 and hippocampus. As for the
α1, α2, α5 GABAAR subunits, the Sysy anti-α3 GABAAR specificity has been
checked by Western-blotting and the correct peptide size was detected (Sysy
communication). The signal could also be blocked by pre-adsorption with the
specific residues of the corresponding α-subunit. Sysy has also checked cross-
reactivity on cells over-expressing the different GABAAR α-isoforms. The Sysy
anti-GABAAR antibodies have been sent to a collaborating academic group of Sysy
who confirmed the expected tissue distribution by immunohistochemistry.
Regarding the Fritschy laboratory antibodies, different amino-acid sequences than
Sysy were used: α1 subunit residues 1–16, α2 subunit residues 1–9, α3 subunit
residues 1–15, and α5 subunit residues 1–29. All the Fritschy antibodies used here
were raised in guinea pig. The dilutions of the antibodies were 1:1000 for every
subunit. Immunocytochemical characterization of these polyclonal antibodies has
been previously described20,32,95,96. Their specificity has been evidenced by using
mutant mice lacking the α1, α2, α3, α5 subunit genes. Immunocytochemistry
showed a complete absence of immunolabeling of the GABAA α1, α2, α3,
α5 subunits in α1, α2, α3, α5 knockout mice97,98. These antibodies have also been
well characterized and used immunohistochemically in human tissues, including
spinal cord30,99–101. The anti-β3 GABAAR subunit antibody was graciously pro-
vided by Dr. Werner Sieghart. This antibody was raised in rabbit against the
maltose-binding protein and amino-acids 345-408 of the rat β3 subunit, part of
the large intracellular loop between putative transmembrane domains M3 and
M4102–105. The monoclonal anti-β2,3 GABAAR antibody (Millipore Catalog
#MAB341, IgG1, clone Bd17) was raised in mouse against the purified GABAAR
β-chain from bovine cortex and has been tested in rat103,104.
The GlyR α1 subunit was detected with a monoclonal antibody (mAb2b, mouse,
1:1000; Sysy; catalog #146111)106–109. This monoclonal antibody was raised against
a peptide coupled to KLH corresponding to amino-terminal residues 1–10 of the
human α1 subunit110 and showed a single band of 48 kDa on Western blot (data
supplied by SySy).
A mouse monoclonal antibody108,111, raised against purified rat gephyrin, was
used in this study (1:1000; Sysy; catalog#147011 mAb7a antibody). The anti-
gephyrin mAb7a antibody is highly specific for immunohistochemical
investigations of gephyrin as documented in many studies attesting the complete
absence of staining in gephyrin knockout mice112,113. This antibody does not
interfere with isolated domains of gephyrin involved in its own gephyrin clustering
and do not interfere neither with the GlyR nor GABAAR clustering at inhibitory
postsynaptic sites114. As gephyrin immunolabelling identifies a protein associated
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with the postsynaptic membrane at inhibitory synapses, its colocalization with
GlyR or GABAAR subunits was used as a marker of the postsynaptic location of
these receptors20,115.
The usual strategy of co-immunostaining (i.e., primary antibodies followed by
secondary fluorescent antibodies) of gephyrin (mAb7a) together with α1 GlyR
(mAb2b) or β2,3 GABAAR (Bd17) could not be applied because the primary
antibodies are both mouse monoclonals. To avoid cross-reactions of the secondary
antibodies detecting two types of mouse primary antibodies, we modified the
protocol. We eliminated the secondary labeling step of gephyrin by using the
fluorophore pre-coupled mAb7a anti-gephyrin antibody (1:1000; Sysy #147011C3;
anti-gephyrin Oyster-550 nm). Co-immunostainings of anti-gephyrin-Oyster with
anti-α1 GlyR (or anti-β2,3 GABAAR) antibodies were processed sequentially as
follow: (i) in a first step, the α1 GlyR (or β2,3 GABAAR) were detected using anti-
α1 GlyR (or anti-β2,3 GABAAR) primary antibodies (12 h at 4 °C diluted in PBS
containing 4% normal goat serum and then rinsed 4 × 5min). (ii) Then, the anti-
α1 GlyR (or anti-β2,3 GABAAR) primary antibodies were revealed by a goat anti-
mouse Alexa 647 cross-adsorbed secondary antibody (ThermoFisher Scientific
catalog# A-21235; 1:500; 1.5 h at room temperature, rinsed in PBS 4 × 5 min).
(iii) Finally, gephyrin was directly revealed by the fluorescent anti-gephyrin-Oyster
primary antibody (mAb7a, 1:1000 for 1.5 h at room temperature; rinsed 4 × 5 min
in PBS). To check the cross-reaction-free labeling using two primary antibodies
raised in the same species, we made sequential co-immunostainings of the anti-
gephyrin-Oyster antibody with a mouse monoclonal anti-CGRP antibody (1:2000;
Sigma #C7113) instead of α1 GlyR (mAb2b) or β2,3 GABAAR (Fig. 2 and
Supplementary Fig. 10). We had shown in a previous report20 that gephyrin was
absent from CGRP-containing primary afferent terminals using the regular
primary/secondary protocol. Here, by using the sequential immunostaining
protocol with anti-gephyrin-Oyster antibody, we confirmed the absence of
gephyrin in CGRP(+) terminals: a non-significant proportion of CGRP(+) pixels
(5.8 ± 0.7%) was overlapping with the gephyrin-oyster mask (Supplementary
Fig. 10b–d; n= 6 naive rats; 24 slices). To conclude, the control of the sequential
immunostainings confirms the absence of cross-reaction of the primary mouse
anti-gephyrin-Oyster antibodies with the secondary Alexa647 anti-mouse
antibodies (Supplementary Fig. 10).
Calcitonin gene-related peptide (CGRP) immunoreactivity was used as a
specific marker of nociceptive peptidergic afferent terminals (not present in any
other types of axons in the dorsal horn)116–119. The polyclonal anti-CGRP
antibody (1:2000, Sigma catalog #C8198) was raised in rabbit using synthetic rat
CGRP conjugated to KLH as the immunogen. This antibody specifically recognizes
the CGRP C-terminal segment (amino-acids 24 to 37) of rat CGRP. This antiserum
shows no cross-reactivity with any other peptide except human CGRP and rat and
human β-CGRP (data supplied by Sigma); staining was completely abolished
when the antiserum was pre-absorbed with rat CGRP. For supplementary Fig. 10,
the monoclonal anti-CGRP antibody (1:2000, Sigma catalog #C7113) raised in
mouse was used (see explanation for the co-immunolabeling with GephO
above). Isolectin-B4 (IB4)-binding was used as a marker of a subset of small
diameter primary afferents, including all of the non-peptidergic nociceptive
terminals80,120–123. IB4 conjugated to Alexa Fluor 488 (1:500, ThermoFisher
Scientific / Molecular Probes, catalog #I21411) has been used in this study to
label non-peptidergic C-terminals.
A monoclonal purified IgG mouse anti-VGAT (Vesicular GABA Transporter)
antibody (1:1000, Sysy, catalog #131011) and a polyclonal detecting the two GAD
isoforms anti-GAD65,67 purified rabbit antibody (1:1000, EMD Millipore, catalog
#AB1511) were used in this study. Western blot reveals a doublet at approximately
65/67 kDa using this antibody. Immunostaining can be abolished by pre-
incubation in 1-10 μg (per ml of diluted antibody) of the corresponding
immunogen peptide common to both isoforms (EMD Millipore, catalog #AG252;
data from EMD Millipore datasheet).
A polyclonal antibody raised in rabbit (Millipore/Upstate, catalog #07-432) was
used in this study. This antibody was raised against a His-tag fusion protein
corresponding to residues 932–1043 of the rat KCC2 intracellular C-terminal124,125.
This antibody is highly specific for KCC2 (KCC2a and KCC2b isoforms) and does
not share any homologous sequences with other KCCs or co-transporters.
Confocal microscopy, image segmentation and measurement. Confocal images
were acquired using an Olympus Fluoview FV1000 confocal laser scanning
microscope (CLSM). Acquisitions were 12-bit images of size 2048 × 2048 pixels
with a pixel dwell time of 12.5 µs. An x20 dry objective was used for low mag-
nification illustrations. An oil-immersion x60 plan-apochromatic objective was
used for high magnification CLSM images which were processed for quantification.
Laser power was adequately chosen to avoid saturation and limit photobleaching.
All the acquisitions were performed with the same laser settings (laser, power,
photomultiplier tube (PMT) settings, image size, pixel size and scanning time). To
study and compare the distribution of the receptors in the dorsal spinal cord in
shams, PNIs or drug-treated spinal cord sections, the first step of the quantification
was to manually define specific regions in an image acquired with the CLSM.
Homemade MATLAB routines were developed in order to quantify the different
sets of images acquired. The fluorescent stainings were studied in specific regions
by image binarization of the IB4(+) terminals, the inhibitory presynaptic marker
(GAD65,67 and VGAT), inhibitory postsynaptic marker (gephyrin), and for the
different GABAAR and GlyR subunit clusters. The binarization of such structures
was defined using an object-based method126. The diameter of axon terminal
profiles (IB4, VGAT and GAD65,67) or of postsynaptic contacts (gephyrin) and of
receptor clusters (GABAAR and GlyR) in CLSM images are of the order of the
point spread function (PSF). For this reason, the algorithm was made to recognize
structures of a disc shape with dimensions similar to that of the PSF. The disc
shape filter was applied to the images to amplify structures with similar shapes and,
because of this, the resulting mask was independent of low frequency variations of
diffuse signal in different spatial regions and the analysis was not biased by the
choice of an arbitrary intensity threshold20,127. Binary masks were obtained for
each acquired image. Images with labeling for IB4, VGAT, GAD65,67, gephyrin,
GABAARs subunits and GlyR α1 subunit were used for quantitative analysis. Two
types of analysis were developed to quantitatively measure the effect of PNI and the
effect of pharmacologically tested controls (incubation with VU024055, BDNF or
anti-TrkB antibody) on the spatial distributions of axon terminals, GABAAR and
GlyR α1 subunits. In the region of interest (the superficial dorsal horn), under the
different conditions just quoted above, we started by quantifying the number of
clusters of each marker, which we defined as the number of distinct PSF-scale
structures per unit area (µm2)20,127. The number of clusters were reported as
percentage of values from either sham or control spinal cord sections. In addition
to this first measurement, we also measured the fluorescence intensity in intensity
unit (i.u.) of 12-bit images of GABAAR and GlyR α1 subunits present at inhibitory
postsynaptic sites (within the gephyrin binary mask). For simplicity and for proper
comparison between subunit types labeled by immunofluorescence, every analysis
was normalized by the appropriate controls. The main goal of this is to present the
measurements independently of the variable affinities of the antibodies used for the
experiment.
Mapping of the KCC2 loss in the spinal cord dorsal horn after PNI. We acquired
tile confocal images from a Zeiss LSM 880 microscope with a Plan-Apochromat
x20 /0.8 plan air Zeiss objective, zoom 5 (11 × 11 images, pixel size 0.66 µm) of IB4
(labeled with Alexa488, Excitation: 488 nm and Emission Filter: 493–535 nm) and
KCC2 (labeled with Cy3, Ex: 561 nm and Emission Filter: 566–625 nm) immuno-
cytochemistry labeling. Example images acquired for each labeling are presented in
Supplementary Fig. 4. IB4 Images were compared to a selected reference image
from the set. Each image was manually translated and rotated to maximize the
IB4 structure overlap representing the lamina II. The same transformation was then
applied to each corresponding KCC2 image. For each type of images, the images
were averaged. This protocol was applied for slices from shams (N= 3 rats, 17 sli-
ces) and PNIs (N= 3 rats, 11 slices). To remove the high frequency fluctuations, a
Gaussian filter with 20 µm standard deviation was applied to all KCC2 images. We
then designed binary masks of KCC2 areas of interest for all sections, and we only
considered the intersection of all these binary masks. In this region, we computed
the relative difference, pixels-per-pixel, between the KCC2 average of PNI rats and
the one of sham rats ΔKCC2 ¼ KCC2ðPNIÞKCC2ðshamÞKCC2ðshamÞ
 
. Specific regions of laminae I
and II were chosen including the subregions that suffered from the largest loss of
IB4 and others where the IB4 labeling was conserved. A deeper region in the dorsal
horn corresponding to the laminae III-IV (>180 µm from the white matter128 was
also added to the analysis for comparison. Histograms of the KCC2 relative dif-
ferences were calculated and are presented in Supplementary Fig. 4.
Enhanced resolution microscopy using multi-array Airyscan. While super-
resolution approaches129 have been very instrumental to decipher biological
structures at the nanoscale level in some special circumstances (i.e., isolated cells,
brain slices)130–132 current super-resolution techniques still do not effectively
provide significant improvements in resolution in sections of the thickness nor-
mally used for immunocytochemistry particularly if extensive field of view need to
be studied129. This is because improvements in spatial resolution always come in
pair with sacrificing image speed acquisition – hence ability to scan large fields of
view—and fluorophore flexibility (i.e., very long scan times causing photobleaching
limitations). In addition, current super-resolution approaches provide limited
multicolor imaging capability necessary for the type of analysis we performed. And
these limitations are compounded for tissue-based quantification. Thus, currently,
leading super-resolution optical techniques do not provide the required throughput
and flexibility to achieve realistically the type of large-scale analysis that we con-
ducted in this study. Beyond the fact that super-resolution would not provide the
throughput needed to conduct the quantification we achieved, it is our contention
that super-resolution was not needed to address the question we asked. Indeed, to
estimate the intensity of well separated clusters as in the system we studied (i.e., the
average gephyrin cluster density was 10.5 ± 0.7 and 14.9 ± 0.7 (mean ± S.E.M. for
N= 14 rats) per 100 µm2 in laminae I and II, respectively), conventional fluor-
escence microscopy is sufficient and allows an unequaled flexibility to investigate a
large number of synapses in single images. Fluorescence intensity is linearly pro-
portional to emitter concentration over a large dynamic scale. This is what allows
quantitation of receptor distributions and oligomerization states within well
identified clusters over wide fields of view, even with conventional
microscopy37,129,133–138.
To validate that enhanced resolution would not provide significant additional
information, we performed additional measurements using a hybrid solution that
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allows similar flexibility and field of views as confocal microscopy but that was shown
to improve the resolution. A Zeiss LSM 880 microscope equipped with an Airy scan
detection unit was used to generate images with higher resolution than with
conventional confocal microscopy. This LSM modality uses a multi-array detector,
deconvolution and the pixel-reassignment principle to enhance spatial resolution and
signal-to-noise-ratio139. Using a high numerical aperture oil-immersion objective
(Plan-Apochromat 63x/1.4 Oil DIC), we quantified the resolution improvement of our
multi-array detector compared to confocal microscopy using 100 nm diameter
fluorescent nanospheres (Abberior TS 100 nm). The full width half maximum
(FWHM) of the bead intensity profiles showed an ~1.7 improvement compared to
conventional confocal detection (Supplementary Fig. 11). To estimate the resolution
ωFWHMð Þ of each the imaging modality, the FWHM diameters, obtained from the bead
intensity profiles, were deconvolved using the bead diameter value provided by the
manufacturer ωFWHM ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ω2fit  D2beads
p
. We then conducted quantification of
GABAAR α2 (Sysy (#224 103) revealed with Cy3 conjugated secondary antibodies;
Excitation 561 nm) in gephyrin (Sysy (#147011) revealed with Alexa 647 conjugated
secondary antibodies; Excitation 633 nm) masks in the same fields of view, within the
same samples, using both modalities: conventional confocal (Meta mode: 530-630 for
GABAAR α2 and 570-758 for Gephyrin) and Airy scan (filters: BP 420-480+ BP 495-
620, 561 nm laser power of 3.0% and PMT master gain of 750, digital gain of 1 for
GABAAR α2 and BP 570-620+ LP 645 633 nm laser power of 20.0% and PMTmaster
gain of 750, digital gain of 1 for Gephyrin), “ChA” 2D SR (super-resolution) capture
Airy scan mode, with a pixel size of 0.073 µm, 16-bit image, 8.19 µs of dwell time per
pixel. Zoom was of 1.8x and pinhole of 2.5 A.U. as requested by Zeiss. The results show
that the intensities integrated between the two modalities correlate (Supplementary Fig.
11h), indicating that the results obtained using the confocal modality are valid to draw
the conclusions we drew.
Real time qPCR, mRNA extraction and cDNA preparation. TRIzol Reagent
(Invitrogen) was used to isolate total RNA from tissues. Briefly, 1 ml TRIzol
Reagent was added per 50–100 mg of tissue sample. Then tissue was homogenized
with power homogenizer according to the following procedure: Incubate the
homogenized sample for 5 min at room temperature, and then add 0.2 ml of
chloroform per 1 ml of TRIzol Reagent. Tubes were shaken vigorously by hand for
15 s, and incubated for 2–3 min at room temperature. Samples were centrifuged at
12,000 g for 15 min at 4°C. The aqueous phase (upper layer) of the sample was
transferred into a new tube and 0.5 ml of 100% isopropanol were added per 1 ml of
TRIzol Reagent used for homogenization. Samples were incubated at room tem-
perature for 10 min and then centrifuged at 12,000 g for 10 min at 4°C. Super-
natants were removed from the tubes, and pellets were washed with 1 ml of 75%
ethanol per 1 ml of TRIzol Reagent. Samples were centrifuged at 7500 g for 5 min at
4°C. Ethanol was discarded and the RNA pellet was air dried. In order to measure
the concentration of RNA, the RNA pellet was dissolved with DEPC H2O. 1 µg
total RNA was reverse-transcribed into cDNA by SuperScript TM III Reverse
Transcriptase (Invitrogen). Oligo (dT)18 was used as primers. Real-time qPCR.
PCR was performed with equal amount of cDNA in the LightCycler 480 system
(Roche) using LightCycler® 480 SYBR Green I Master (Roche). Reactions (total
20 μl) were incubated at 95 °C for 5 min, followed by 45 cycles of 30 s at 95 °C, 30 s
at 58 °C, and 1 min at 72 °C. Water controls and no reverse transcriptase negative
control were included to ensure specificity. We quantified the relative expression of
Gabra1,2,3 and GPHN mRNAs in sham vs PNI rats. The amount of these targeted
mRNAs was normalized to the expression of two reference house-keeping genes
TFRC (Rat Transferrin Receptor) and Gusb (Rat Glucuronidase-β). Primer effi-
ciencies were integrated to the calculation of the final target/reference gene mRNA
ratio by the use of LC480 converter and LinRegPCR softwares. All PCR primers are
listed in Supplementary table 1.
Gabra2 mRNA detection in inhibitory and excitatory neurons. As in Lorenzo
et al. 2008128, neurons were detected by IHC using NeuroTrace 435/455 Blue
Fluorescent Nissl Staining (ThermoFisher Scientific catalog #N-21479) and IB4
lesion in the spinal dorsal horn of PNI animals by using IB4-488 (ThermoFisher
Scientific, catalog #I21411 as above). Numbers of transcripts were detected by using
the RNAscope fluorescent multiplex assay for fixed frozen tissue of L4–L5 rat
lumbar spinal cord segments of 18 μm thick sections (Advanced Cell Diagnostics,
ACD)140. Probes were designed and provided by Advanced Cell Diagnostics, Inc.
The number of Gabra2 mRNAs (detected by probe catalog #410761-C1) was
determined in inhibitory and excitatory neurons (respectively detected by probe
#424541-C2 against Slc32a1 for the detection of VGAT positive neurons, and by
probe #317011-C2 against Slc17a6 for the detection of VGluT2 positive neurons).
The probe detections were performed using the RNAscope Fluorescent Multiplex
Reagent Kit (catalog #320850) and visualize with a Zeiss Lsm 880 (Plan-Apoc-
hromat 63x/1.4 Oil DIC M27 objective, zoom 0.7 and pixel size of 0.094 µm).
Z-stacks of 6 images totalizing 5 μm thick section were analyzed. Detection of
Neuronal Nissl(+ ) cell bodies was done using a custom adaptive threshold
algorithm in MATLAB. We first applied a 50X50 pixel kernel square convolution,
whose pixel sum is equal 1, in order to obtain an image with local average for each
pixel. Then, the original image was subtracted from the local average image to
obtain an off-set image. Brighter neuronal cell bodies were identified as pixels
having intensities higher than the mean plus 0.5-1 standard deviation of the offset
image. The adaptive algorithm was coupled to a morphological analysis that scores
cell bodies having a size of more than 500 pixels and maximum eccentricity of 0.98.
The function ‘imfill’ from MATLAB was applied to the sub-threshold cell bodies to
close possible holes inside the Nissl staining. The neuronal somata were then
extracted from the original image based on their bounding-box, the same
bounding-box was used to crop the corresponding RNAscope images. RNAscope
images were randomly chosen by MATLAB in order to run blind analysis. Back-
ground definition and RNA fluorescent dots were manually drawn by the user
using ‘imellipse’ function in MATLAB. The inhibitory Nissl neurons were con-
sidered as inhibitory if they expressed at least one positive fluorescent dot Slc32a1
(+) mRNA, and as excitatory if the express at least one positive fluorescent dot
Slc17a6 (+)mRNA. The number of Gabra2(+) RNA fluorescent dots were counted
in each Slc32a1(+) and Slc17a6(+) Nissl neurons and plotted.
Spatial intensity distribution analysis. SpIDA is an analysis technique that was
developed to quantify complex mixtures of oligomerization states using fluorescent
microscopy images36,133,141. SpIDA can measure the concentration and oligomeric
states of proteins revealed with fluorescent probes (e.g., fluorescent proteins,
fluorescent antibodies). It was previously used to reveal the dimerization of many
types of receptors from various cell systems37. We sought to investigate the oli-
gomerization states of α1 and α2 GABAARs in inhibitory synapses and quantify the
spatial distribution shift that occurs after peripheral nerve injury (PNI). We first
quantify the monomeric quantal brightness of our fluorescent labeling complex
obtained from slices labeled solely with secondary antibodies133. As the dominant
composition of GABAARs appears to be two α's, two β's and one γ subunit142 a
monomer-dimer SpIDA model, using the monomeric quantal brightness, can be
applied to study the distribution of any of its subunit type. Because postsynaptic
sites are not larger than few beam areas, a single site does not contain a sufficient
number of independent pixels to obtain accurate results and averaging over many
postsynaptic sites was necessary. To do this, we built a histogram with all the pixels
for each GABAAR subunit labeling that was contained within labeled synapses
(gephyrin clusters in Figs. 1e, 2a, b) as previously demonstrated36. To measure the
direct effect at synapses, the values (monomers+ dimers) from shams and PNIs
are representative of the average number of receptors at the synapse (Fig. 2g–i)
assuming the mean cluster size obtained for gephyrin masks (Radius ∼ 0.35 µm).
KCC2 intensity profile analysis. We sought to quantify the KCC2 expression level
at the cellular membrane of single cells. For each immunocytochemistry confocal
image, where KCC2 was fluorescently labeled, the average non-specific staining
level, quantified in isolated white matter regions, was first subtracted from the
whole image. We then manually selected neurons, in the Lamina II of the SDH,
which could undoubtedly be defined. We made sure that the neurons selected for
this analysis had membrane sections that could be clearly identified on both sides
and intracellular signal that was minimally contaminated by out of focus mem-
brane signal (Fig. 5a, c). The intensity profile KCC2 immunostaining of each
neuron was then quantified along the selected line. We estimated the position of
the membrane, on each side, along the profile by fitting the two maxima. This
process was repeated for all selected neurons and for each rat, the average mem-
brane profile was calculated using all the profiles from individual cells. Finally, the
final intensity profile for each condition was generated by averaging the profiles
from all single rats (Fig. 5b, d). We compared the profiles from sham (77 profiles
from n= 8 rats) vs. PNI (190 profiles from n= 8 rats) rats (Fig. 5b) and PNI+
VEH (268 profiles from n= 12 rats) vs. PNI+ CLP257 (310 profiles from n=
17 rats) rats (Fig. 5d).
Membrane KCC2 index analysis. As previously presented51,71, spinal dorsal
horn (SDH) corresponds to a complex dense network of cells in which the majority
of single cells cannot be clearly separated or delineated. We developed an algorithm
to discriminate the KCC2 membrane population from the KCC2 intracellular in
the SDH. For this analysis, we defined an index that reflects the global membrane
KCC2 intensity and, hence, is not based on manually selection of large easy to
delineate cell bodies (Fig. 5e). For each image of an immunostained slice, the
average non-specific staining level, quantified in isolated white matter regions, was
first subtracted from the whole image. The intensity of the intracellular KCC2
immunostaining was then defined in regions that could undoubtedly be identified
as neurons of the SDH. Finally, a large region of the SDH was delineated from
which the averaged KCC2 pixel intensity was calculated. Even if one could perfectly
delineate the cell membrane, the measurement would still be heavily tainted by the
presence of intracellular KCC2 due to the optical resolution as determined by the
point spread function. For this reason, to obtain the KCC2 intensity corresponding
to the membrane staining, the average intracellular KCC2 intensity value was
subtracted to this average KCC2 intensity in the chosen region. This membrane
KCC2 intensity index was measured for every rat and the values were averaged.
This index is robust and global because it includes many neuronal cell bodies and
dendrites and does not depend on arbitrarily visually selected neurons. This index
was measured for every rat and the values were averaged using four to six spinal
cord sections per rat in every condition (n= 8 rats for sham, n= 8 rats for PNI,
n= 12 rats for PNI+ vehicle, n= 17 rats for PNI+ CLP257). Single profile plots of
the KCC2 immunostaining intensities in identified dorsal horn neurons are also
shown in Fig. 5a, c.
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Transmission electron microscopy. Four rats were anesthetized with Equithesin
and perfused transcardially with a mixture of 4% formaldehyde obtained from
paraformaldehyde (PFA), 15% picric acid and 0.1% glutaraldehyde in 0.1 M
phosphate buffer (pH 7.4) for 30 min, followed by the same mixture without
glutaraldehyde for 30 min and then for 30 min with a solution of 10% sucrose in
0.1 M phosphate buffer (pH 7.4). Spinal cord segments L4–L5 were collected and
placed in 30% sucrose in 0.1 M phosphate buffer overnight at 4oC. Subsequently,
spinal cord segments were snap-frozen by immersion in liquid nitrogen, thawed in
0.1 M phosphate buffer at room temperature and cut into 50 μm thick transverse
sections with a Vibratome 1000 Plus (TPI). Sections were then incubated for
30 min in 1% sodium borohydride. After extensive washing (5x12 min) in PBS,
sections were incubated in 0.5% BSA in PBS for 30 min and then in 5% normal
goat serum (Gibco) for 30 min. Then, sections were incubated at 4 °C for 48 h the
rabbit polyclonal anti-KCC2 antibody (1:100; Millipore/Upstate, catalog #07-432)
also used for confocal microscopy, diluted in PBS with 0.1% BSA. Then sections
were washed in PBS (3x10 min), then in 0.1% fish skin gelatin and 0.8% BSA in
PBS (2x5 min) and incubated in goat anti-rabbit IgG conjugated to 1 nm gold
particles (1:200; Biocell, UK) for 12 h at 4 °C, to label the KCC2 C-terminal tail.
Sections were then washed and incubated in 2% glutaraldehyde in PBS for 10 min,
washed in PBS (3x5 min), rinsed in distilled water (2 min) and then washed in
citrate buffer (3x5 min). Silver intensification of the gold particles was performed
for 10 min using a silver enhancement kit (Amersham, UK). Sections were rinsed
twice in deionized water then for 5 min in phosphate buffer and incubated in 1%
osmium tetroxide (OsO4) in phosphate buffer. Finally, the sections were dehy-
drated through ascending ethanol concentrations and propylene oxide. Sections
were then flat-embedded in Epon (for details see143). The regions of interest were
selected using light microscopy and re-embedded in Epon blocks. Ultrathin sec-
tions were cut with a Reichert ultramicrotome and collected on Formvar-coated
one-slot copper grids. The sections were counterstained with uranyl acetate and
lead citrate before observation on a Philips 410 LS electron microscope equipped
with a Megaview II digital camera.
Rat spinal cord slices preparation and drug incubation. Adult male
Sprague Dawley rats (around 60 days old) were anesthetized with a mixture of
ketamine/ xylazine (respectively 0.875 and 0.125 mg kg−1) and perfused intracar-
dially for 15–20 s with ice-cold oxygenated (95% O2 and 5% CO2) sucrose-
substituted ACSF (S-ACSF) containing (in mM): 252 sucrose, 2.5 KCl, 1.5 CaCl2,
6 MgCl2, 10 glucose, 26 NaHCO3, 1.25 NaH2PO4, and 5 kynurenic acid, pH 7.35;
360–370 mOsm. The rats were then rapidly decapitated, and the spinal cord was
immediately removed by hydraulic extrusion and immersed in ice-cold S-ACSF for
1–2 min.
For immunohistochemistry on slices, lumbar segments (10 mm long) were
isolated and glued vertically (rostral side down), their lateral side leaning on a V-
grooved agar block itself glued on a metal platform with cyanoacrylate cement. In a
cutting chamber filled with oxygenated ice-cold S-ACSF, 600 µm thick transverse
sections were cut with a vibrating blade microtome (VT1200S; Leica, Germany).
The slices were then incubated in S-ACSF at room temperature (21–25 °C) for
5–15 min and subsequently transferred to a storage chamber filled with oxygenated
normal ACSF containing (in mM): 126 NaCl, 2.5 KCl, 2 CaCl2, 2 MgCl2,
10 glucose, 26 NaHCO3, 1.25 NaH2PO4, pH 7.3; 300–310 mOsm at room
temperature. The storage chamber was then placed in a warming bath to let the
slices recover at 34 °C for about 30–60 min. Half the slices were then transferred to
another storage chamber and exposed to human Brain Derived Neurotrophic
Factor (BDNF, 50 ng ml−1; PeproTech, Rocky Hill, USA) and or KCC2 blocker
VU0240551 (VU, 15 µM; Tocris, Cookson, UK) and/or a blocker of TrkB receptor,
anti-TrkB antibody, which also acts as a function blocking antibody49,57 (ATB,
5 µg ml−1; R&D Systems). After 3 h incubation, slices were frozen on dry ice and
stored at -80 °C for further immunohistochemistry processing.
For electrophysiology, following hydraulic extrusion of the spinal cord, the
lumbar segment was isolated and cut in 400 µm thick parasagittal slices, gluing the
lateral side down. The same recovering procedure was applied as for
immunohistochemistry. All drugs (including BDNF) were bath-applied and
prepared in deionized water as 1000× concentrated frozen stock solution aliquots.
After 30–60 min incubation in the storage chamber at 34 °C for mIPSC recording
or at room temperature for EGABA and repetitive stimulation procedures, slices
were transferred to a recording chamber under an upright microscope (BX61WI;
Olympus, Tokyo, Japan) equipped with infrared gradient contrast and water
immersion-objectives for visualization of neurons in thick live tissue.
Whole-cell recording from superficial dorsal horn neurons. For whole-cell
voltage-clamp recordings, patch pipettes were pulled from borosilicate glass
capillaries (with an inner filament, WPI) using a two-stage vertical puller (PP-83;
Narishige, Tokyo, Japan). Recordings were obtained at room temperature, by
lowering the patch pipette (<5 MΩ onto the surface of visually identified neurons
in superficial dorsal horn, up to 100 µm from the interface between white and gray
matter. Neurons with a healthy appearance presented a smooth surface, and the
cell body and parts of the dendrites could be clearly seen. While monitoring current
responses to 1 mV pulses, a brief suction was applied to form >1 GΩ seals. A
Multiclamp 700B amplifier connected to a Digidata 1440 A data acquisition system
and controlled through Clampex software (all from Molecular Devices, Sunnyvale,
CA) were used for the recordings. The access resistance was monitored throughout
each experiment. Only recordings with access resistance between 7 MΩ and
30 MΩ, and with stable access (no more than 50% variation) throughout the entire
administration of drugs were considered acceptable for analysis.
Mini-IPSCs recordings. The slices were perfused at 2 ml min−1 in a closed circuit
with 50 ml of oxygenated ACSF containing the drugs. The closed-circuit perfusate
was changed every 1.5 h. All GABA mIPSC recordings were performed at 32 °C.
The pipettes were filled with an intracellular solution composed of (in mM):
100 CsCl, 10 HEPES, 2 MgCl2, 2 ATP, 0.4 GTP, 0.4 CaCl2 and 2 EGTA (or 1 CaCl2,
11 BAPTA), 0.2% Lucifer yellow and 0.2% Neurobiotin (Vector Labs). The pH was
adjusted to 7.2 with CsOH, and the osmolarity ranged from 260 mOsm to 280
mOsm. GABAA mIPSCs were isolated in voltage clamp in presence of the gluta-
mate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 10 µM;
Tocris, Cookson, UK), NMDA receptor antagonist D-2-amino-5-phosphonovaleric
acid (DAP-5; 40 µM; Tocris, Cookson, UK), sodium channel blocker tetrodotoxin
(TTX, 1 µM; Alomone Labs, Jerusalem, Israel), and glycine receptor antagonist
strychnine (0.5 µM, RBI, Natick, USA) at a holding potential of −60 mV. Traces
were low-pass filtered at 3 kHz and stored directly on computer. Off-line, the
recordings were low-pass filtered at 1 kHz on a computer using the Strathclyde
Electrophysiology software (WinEDR; by J. Dempster, Department of Physiology
and Pharmacology, University of Strathclyde, Glasgow, UK). The traces were then
analyzed with respect to decay time constants with locally designed software.
EGABA measurement. EGABA was measured under Cl− load at room temperature,
as previously described47,68. The following pipette solution was used (in mM):
115 K-methylsulfate, 25 mM KCl, 2 MgCl2, 10 HEPES, 4 ATPNa, 0.4 GTPNa,
pH 7.2. Under these conditions, and assuming a [HCO3−]i of 16 mM78, the the-
oretical value of EGABA as calculated by the Goldman-Hodgkin-Katz equation is
−37 mV. Muscimol (0.5 mM) was applied locally for 30 ms by pressure ejection
through a micropipette in presence of in the presence of bath-applied CNQX
(10 µM) and APV (40 µM) and TTX (1 µM). The puff pipette was aimed toward
the center of the neuronal somata, approximately 5 μm away from the recording
pipette. Experimental EGABA was extrapolated from the GABAA I-V relationships.
Traces were low-pass filtered at 4 kHz and analyzed with Clampfit software
(Molecular Devices).
Repetitive stimulation of inhibitory transmission. For electrical stimulation of
the inhibitory synaptic transmission, the following pipette solution was used (in
mM): 135 K-methylsulfate, 5 KCl, 2 MgCl2, 10 HEPES, 4 ATPNa, 0.4 GTPNa, pH
7.2. Evoked IPSCs (eIPSCs) were elicited by electrical stimulation (100 µA, 200 µs)
delivered focally via a patch micropipette placed in the vicinity of the recorded cell
in the presence of CNQX (10 µM) and APV (40 µM), as previously described144.
Trains of stimuli (24 pulses – 20 Hz) were delivered every 20 s at 0 mV47,68,77. The
average of ten consecutive stable stimulations for each holding potential was used
for subsequent analysis. After every stimulation, peak amplitude was normalized to
the first eIPSC. Fits follow an exponential decay relationship between eIPSC
amplitude and number of eIPSC. Sections were pre-incubated in ACSF or in
CLP257 (5 μM or 100 µM) and L838,417 (2 µM) was bath applied28 (room tem-
perature) from stock solutions in DMSO (1000 times more concentrated).
CNS penetration and clearance of CLP257 after i.p. injection. Concentrations of
CLP257 were measured by LC/MS (Liquid Chromatography/Mass Spectrometry)
in brain homogenates obtained 30, 60, 120, 240 and 420 min after 100 mg kg−1 i.p.
injections. CLP257 concentration was reported in pmol·g−1 (or nM) or brain
weight (assuming a brain tissue density of 1 g ml−1; Supplementary Fig. 7). In
short, CLP257 was administered i.p. in 20% HPCD to adult male Sprague-Dawley
rats (n= 3). At the mentioned time points, animals were decapitated using guil-
lotine, and brains carefully removed. They were washed in saline, dissected long-
itudinally, and snap-frozen in liquid nitrogen. Brain samples were homogenized in
4x volume of sterile water followed by methanol extraction, and dosage of CLP257
was done by LC/MS.
Pharmacology. In this section, we characterize the pharmacological properties of
L838,417 and CLP257. All drugs were administered intraperitoneally (i.p.) using
single injections (4 ml) to adult male Sprague-Dawley rats at the opposite side of
the cuff surgery. Drug injections and behavioral testing that follows were done
blind to surgery, drug type and drug dose. Drugs were injected one hour prior to the
behavioral testing that lasts four hours. In the behavioral comparison between
sham and PNI animals L838,417 was diluted in 0.5% methylcellulose and 0.25%
Tween 20 diluted in distilled water. In the dose-response curve, L838,417 was
diluted in 20% 2-hydroxypropyl-β-cyclodextrin (20% HPCD) in concentrations that
varied from 0.05 mg kg−1 (0.125 µmol kg−1) to 20mg kg−1 (50 µmol kg−1). The
chloride extrusion enhancer CLP257 (ref. 28) was also diluted in 20% HPCD and
administered i.p. from 5mg kg−1 (16.2 µmol kg−1) to 150mg kg−1 (488mol kg−1).
For the study of KCC2 immunostaining intensities and profiles in the spinal
cord with CLP257, CLP257 was diluted in HPCD and administered by two suc-
cessive intrathecal (i.t.) injections separated by 30min (total dose of 40mg kg−1
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i.e., 130 µmol kg−1 i.t.). Twelve rats received vehicle (HPCD) i.t. injections and
seventeen rats received CLP257.
For dose-response curves, the WD50 thresholds were reported as maximum
possible analgesia (MPA) over four hours calculated as follow:
%MPA tð Þ ¼ ½WD50ðtÞ WD50ðpredrugÞ½WD50ðprePNIÞ WD50ðpredrugÞ
 100% ð1Þ
● WD50 tð Þ ¼ 50% paw withdrawal threshold at time point t,
● WD50 predrugð Þ ¼ 50% paw withdrawal threshold after PNI surgery before
drug injection (t= 1 h),
● WD50 prePNIð Þ ¼ 50% paw withdrawal threshold baseline before PNI surgery.
Note that MPA cannot be used in sham rat but just in PNI injured animals.
The data were fitted using the 4 parameter Hill dose-response curve equation:
Y X½ ð Þ ¼ Y0 þ Ymax  Y0ð Þ 
X½ H
X½ H þEC50
H
  ð2Þ
Y X½ ð Þ =MPA; with [X]= drug concentration;Y0=MPA observed with
vehicle; Ymax=Maximal MPA; H=Hill's slope and EC50= drug concentration for
half of the maximal MPA Y EC50ð Þ ¼ 1=2  Ymax þ Y0ð Þð Þ.
To test the possible increase in potency of the two drugs when given
simultaneously, we injected a total volume of 4 ml of combined doses of L838,417
and CLP257 in a fixed dose ratio of ½L838; 417=½CLP257 = 1:55, given the relative
EC50s of the two drugs calculated from the respective dose response curves with a
priori assumption on the collapse at high doses of L838,417 (Fig. 4e, g). We then
built the isobologram of the corresponding dose-response curves with a fixed dose
ratio of R and compared the expected mixture of the two doses that produced an
effect equal to half of the maximal effect produced by the individual drugs and to
the experimental value (see later in methods). To also test the maximal possible
increase in efficacy of the two drugs when given together, we administered single
injections of 4 ml with increasing doses of L838,417 and a constant dose of CLP257
(100 mg kg−1).
If two compounds a and b produce a specified effect that can each be
independently parameterized by a four parameter Hill equation (Eq. 2), the
additive effect of having a½ & b½  can be modeled via the concept of dose
equivalency. Starting with a dose-response curve of individual drugs:
Y a½ ð Þ ¼Y0 þ Yamax  Y0
   ½aHað½aHa þ ðECa50ÞHa Þ and
Y b½ ð Þ ¼Y0 þ Ybmax  Y0
   ½bHbð½bHb þ ðECb50ÞHb Þ :
Then for every dose of drug b, a dose of drug a that provides an equivalent effect
can be calculated using Yð½bÞ ¼ Yða  aeqðbÞÞ, knowing that Yamax  Ybmax . The
principle of dose equivalence and the calculations are presented in further details
in72. Here, it was assumed that both drugs have effects that increase with dose:
aeq bð Þ ¼
ðECa50ÞHa  Ybmax  Y0
   b½ Hb 
Yamax  Y0
   ðECb50ÞHb  Ybmax  Y0   b½ Hbþ Yamax  Y0   b½ Hb
 !1=Ha
:
ð3Þ
To generate the additive theoretical response to the presence of two compounds
a½ & b½ , the dose of drug b has to be transposed to a dose of drug a having an
equivalent effect and, finally, the additive effect can be calculated back using the
one drug dose-response curve:
Y2 drugs a; bð Þ ¼ Y aþ aeq bð Þ
 
:
Comparing the experimental response of the two compounds, H2 drugs a; bð Þ, to
additive theoretical response, Y2 drugs a; bð Þ can reveal the evidence of antagonism
ðH2 drugs a; bð Þ<Y2 drugs a; bð ÞÞ or synergism ðH2 drugs a; bð Þ>Y2 drugs a; bð ÞÞ between
two compounds.
The drug interaction study between L838,417 and CLP257 was based on the
following publications72–74,145. We can also quantify the theoretical additive effect
of varying the concentrations of a and b using the same ratio ðRatiob=aÞ between
the two drugs, ði:e: b ¼ Ratiob=a  aÞ. Comparing Yðaþ aeqðRatiob=a  aÞÞ to the
experimental effect of the same combination of drugs can further reveal evidence
pointing toward purely additive, synergic or antagonistic processes between the two
compounds. We finally define the isobole curve for which a combination of two
drugs induces the same theoretical effect as ECa50. The isobole can be derived using
Eq. 3 by solving aþ aeq bð Þ ¼ ECa50 for all values of a 2 0;ECa50
 
. We define the
theoretical A50 as the intersection of the isobole (Fig. 6c, dashed red line) and the
line corresponding to the fixed dose ratio b ¼ Ratiob=a  a (Fig. 6c, dashed black
line). The observed A50 corresponds to the drug mixture, on the fixed dose ratio
line ðb ¼ Ratiob=a  aÞ, that produces the same effect as ECa50.
In this section, we present how we modeled the effect of the presence of a
collapse on a dose-response pharmacological process. Assuming that the two
processes are independent, the final fitting function, including the effect of the
collapse, can be calculated simply by the multiplication of a normal dose-response
curve without collapse (Eq. 2) and an inverse normalized dose-response curve
representing the collapse C X½ ð Þ ¼ 1 C
Hcol
50
X½ Hcol þCHcol50
 :
YCollapse X½ ð Þ ¼ Y X½ ð Þ  1 C X½ ð Þð Þ: ð4Þ
C50 is the concentration for which the collapse diminished by a factor 2 the effect of
the drug and Hcol is the corresponding Hill slope of the collapse. Using a non-linear
square curve, we obtained the best fit to the data. In Fig. 8b, the three separated
curves are presented for the data obtained for L838,417: the normal dose-response
curve (dashed red), the collapse (dashed blue) and the resulting fitting function
(Eq. 4 in pink, Fig. 8b). For this fit, we set the collapse maximum of the normal
dose-response curve to the value obtained from Fig. 6g.
Statistical analysis. All data are given as the mean ± S.E.M. Most of the dis-
tributions passed normality tests, so t-test or paired t-test were applied (with Welch
correction because standard deviations were often different between sham and cuff
animals). For dose-response curve analysis, one-way ANOVA test was applied to
compare responses to different dose concentrations of L838,417 or CLP257. When
the distributions were not normal, non-parametric tests were used and differences
between groups were tested by Mann-Whitney test or by Kruskal-Wallis test
with post-hoc Dunn test. Differences were considered to be significant at *P < 0.05,
**P < 0.01 and ***P < 0.001. Number in column of bar graphs indicates the num-
bers of rats analyzed or cells analyzed for electrophysiological recordings.
Mathematical modeling: mIPSC kinetics. The first purpose of the computer
simulations was to explain the following observation: despite an increase in the
number of GABAAR per synapses (in PNI vs. sham rats) indicated by the fluor-
escence immunolabeling of the GABAARs in gephyrin masks analysis (Fig. 2a, c,
g–i), the mean amplitude of the events recorded by electrophysiology do not sig-
nificantly change in both conditions (Fig. 2j). It is known that GABA receptors are
unsaturated during synaptic events146,147 and that the affinity to GABA of α2 and
α3 receptors is smaller than the affinity of α1 receptors38,39. Hence, we hypothe-
sized that a difference in affinity could explain the fact that event amplitudes do not
increase in PNI condition despite an increase in the number of synaptic GABAARs
(thus in the total conductance). To test whether the affinity hypothesis is consistent
with experimental observations, we modeled the channel's dynamics according to
the following scheme:
C0
k1½GABA
$
k2
C1
k3
$
k4
O;
where C0 and C1 correspond respectively to an unbound close state and a bound close
state while O stands for an open state. The transition rates k1, k2, k3 and k4 stand
respectively for the binding rate, unbinding rate, opening rate and closing rate while
[GABA] stand for the concentration of GABA neurotransmitters in the synaptic cleft
modeled by GABA½  ¼ GABA½ maxe
t
τGABA with [GABA]max= 0.63mM and τGABA=
1 ms148–150. This model does not aim to describe all the states of the channels which
include several desensitized states39, we rather aimed for the simplest model able to
explain the experimental data while more complex models would lead to over-fitting.
Assuming that the unbinding rate is the same in PNI and sham conditions
ksham2 ¼ kPNI2
 
, we fitted the seven parameters ksham1 ; k
sham
2 ¼ kPNI2 ; ksham3 ; ksham4 ;
kPNI1 ; k
PNI
3 and k
PNI
4 to satisfy the following seven constraints: (i-iv). We replicated the
rise times and decay times of both sham and PNI conditions as measured in the
present study (Fig. 2j). (v) We imposed that the proportion of open channels at
maximal amplitude in normal (sham) conditions is consistent with previous reports
(>50%)147,151. The β2, 3 GABAAR subunits are representative of most of the GABAAR
subtype composition in the dorsal horn. (vi) In PNI, at gephyrin synaptic sites, the β2,
3 GABAAR subunits increase of 37.2% in immunostaining intensity (Fig. 2c), so
theoretically the total number of GABAA channels is 37.2% higher in PNI compared
to sham, so for similar maximal conductance of GABAARs, the proportion of open
channels has to be 37.2% smaller in PNI (Fig. 2j). (vii) Finally, we computed the
proportion of open channels at steady state for different constant [GABA] values and
chose the parameters so that the EC50 values of [GABA] (not to be mistaken with the
EC50 of drugs discussed in the pharmacology section) in sham is consistent with the
experimentally observed values38 (Fig. 2k). Explicitly, we obtained: ksham1 ¼
40ms1; ksham2 ¼ 0:8ms1; ksham3 ¼ 1ms1; ksham4 ¼ 0:15ms1; kPNI1 ¼ 11:2ms1;
kPNI2 ¼ 0:8ms1; kPNI3 ¼ 0:43ms1 and kPNI4 ¼ 0:06ms1.
Once the values of ksham1 ; k
sham
2 ; k
sham
3 ; k
sham
4 ; k
PNI
1 ; k
PNI
2 ; k
PNI
3 and k
PNI
4 were
obtained, we simulated the time course of conductance during an event in both
PNI and sham conditions (Fig. 2l) accounting for the observation the maximal
conductance 37.2% larger in PNI condition (e.g. the β2,3 GABAAR subunits
increase; Fig. 2c). For illustrative purpose, we added a curve obtained with the PNI
conductance and sham kinetics (Fig. 2l). Our model also allowed simulating dose
response curves for the steady-state proportion of open channels as a function of
[GABA] in the synaptic cleft (Fig. 2k) in sham and PNI conditions. This was
compared with the experimental dose response curves for various GABAA channel
subtype compositions (Fig. 2k)39,41. The kinetics of GABAAR channel opening
depend on its composition. These channels display different affinity for [GABA]
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depending on the type of β subunit, assuming identical α subunit composition, and
their kinetics of channel opening follows this trend: β3 > β2 > β139,41. The three
arrows in Fig. 2k show that the kinetics of α2β2γ2 is slower than the
α2β3γ2 stoichiometry.
Mathematical modeling: inhibitory current. We also performed computer
simulations to explain the experimental analgesic effect under the assumption that
the analgesic effect of CLP257 and/or L838,417 is due to the effect of these drugs on
the net anionic current through GABAARs. We investigated whether the hypoth-
esis that L838,417 and CLP257 act on different effectors (the GABAergic con-
ductance and the KCC2 Cl− extrusion capacity) is compatible with the
experimental synergistic effect (Fig. 6b, c, f, g).
Anionic current. GABAARs are permeable to both Cl− and HCO3− anions though
the permeability to Cl− ions is about 4 times larger than the permeability to
HCO3−79,152. We thus modeled the anionic current (Ianion) as Ianion ¼ ICl þ IHCO3
where ICl ¼ gCl  V  EClð Þ and IHCO3 ¼ gHCO3  ðV  EHCO3 Þ. The apparent con-
ductances with respect to Cl− and HCO3− anions are fractions of the total inhi-
bitory conductance (ginh). Explicitly, we have gCl ¼ x  ginh and
gHCO3 ¼ 1 xð Þ  ginh. Though this is a simplification with respect to the more
complete Goldman-Hodgkin-Katz (GHK) flux formalism, this is sufficient for the
qualitative purpose of the present investigation.
The equilibrium value of ECl. As described in Dijkstra et al.153, the flux of Cl−
through the KCC2 cotransporter is given by JCl ¼ UKCC2  ðECl  EK Þ. The strength
of the KCC2 cotransporter is denoted by UKCC2 and is in units of mol·s−1·V−1
while the Cl− flux has units of mol  s1. The Cl− current through KCC2 is in turn
given by ICl;KCC2 ¼ UKCC2  F  ECl  EKð Þ in units of C  s1, where F is the
Faraday constant. To simplify notation and allow easier comparison between
synaptic Cl− influx and efflux through KCC2, we set gKCC2 ¼ F  UKCC2 and obtain
ICl;KCC2 ¼ gKCC2  ECl  EKð Þ. We assume the value of ECl to be such that Cl−
concentration is at equilibrium, that is the Cl− synaptic influx and extrusion
through KCC2 cancel each other out, this yields
ECl ¼
ginh  Vmean þ gKCC2  EK
ginh þ gKCC2
where Vmean is the time averaged value the membrane potential taken to be
Vmean=−60 mV. We can thus write the value of ECl as a function of ginh and
gKCC2, namely ECl ¼ ECl ginh; gKCC2ð Þ and in turn the net effective anionic current
as a function of gKCC2 and gCl
Ianion ¼ Ianion ginh; gKCC2ð Þ ¼ x  ginh  Veff  ECl ginh; gKCC2ð Þð Þ
þ 1 xð Þ  ginh  ðVeff  EHCO3 Þ
where Veff is the value of Eanion for which there is no effective inhibition (no impact
on the firing rate of the neuron). Due to shunting inhibition, this value is more
depolarized (-55 mV) than the mean value or resting value of membrane
potential154.
The values of ginh and gKCC2 in PNI with no drug administration. In order to
investigate the effect of increasing ginh and gKCC2 through drug administration, we
first had to infer their baseline values (i.e., the basal values in PNI condition) that
we denote gPNIKCC2 and g
PNI
inh . As we are only interested in relative increase in anionic
current, without loss of generality we set gPNIinh ¼ 1. The PNI value of gKCC2 was set
so that Eanion ≈ -65 mV according to internal data. This yielded gPNIKCC2  0:81 which
is normalized to gPNIinh . From this and using the relation Ianion ¼ Ianion ginh; gKCC2ð Þ
define above, we related the increase in net anionic current to the increase in ginh
and gKCC2:
ΔIanion ¼ ΔIanion Δginh;ΔgKCC2ð Þ: ð5Þ
The Δ annotation means the relative change of a quantity normalized to its PNI
value. Since the goal of our mathematical model is to explain the relationship
between the drug dose and the observed analgesic effect, we also need to infer the
relation Effect ΔIanionð Þ, the analgesic effect as a function of the increase in anionic
current, as well as the relations Δginh L838; 417ð Þ and ΔgKCC2 CLP257ð Þ relating the
drug concentrations to their respective effectors activity.
The maximal effect of L838,417. We define Δginh as the value of inhibitory
conductance for which the net anionic current is maximal given that gKCC2 is fixed
at PNI value. We assume that this corresponds to the maximal analgesic effect of
L838,417 experimentally observed (Ymax ≈ 31%, Fig. 4e). However, the experi-
mental data exhibits and offset of ≈6% corresponding to an analgesic effect in the
absence of drug administration that cannot be explained by the paradigm of an
increase in anionic current. We thus subtracted this offset and worked with the
corrected value ≈ 25%. The value of Δginh was found to be 1.9 and the associated
corresponding relative increase in net anion current was maximal at ≈26%. This
yields Effect 26%ð Þ  25% as well as Δginh 10 mg  kg1
  ¼ 1:9:
The maximal analgesic effect of administrating two drugs. The maximal
analgesic effect of CLP257 experimentally observed was ≈ 25% at 100 mg∙kg−1
Fig. 4g). As above, we took the offset into account and worked with the corrected
value ≈ 19%. Assuming that the analgesia current relation is linear in this range, the
value of ΔIanion corresponding to 19% percent analgesia is ΔIanion ≈ 19.8%.
Inverting the ΔIanion ΔgKCC2;Δginhð Þ relation (assuming that ginh is fixed at PNI
value so that Δginh ¼ 0) gave that the increase of gKCC2 necessary to obtain an
increase of 19.8% in net anionic current is ΔgKCC2 ¼ 34:5%. Interestingly, this is
consistent with recovery of KCC2 expression measured by immunostaining
(Fig. 5g). Given that the maximal analgesic effect of CLP257 occurs for a dose of
100 mg kg−1, we obtained ΔgKCC2 100 mg kg
1  ¼ 34:5%. On the one hand, the
joint administration of 100 mg kg−1 CLP257 and 10 mg∙kg−1 L838,417 yielded an
experimental analgesic effect of ≈ 48% (Fig. 6f, g) which we corrected accounting
for the offset to ≈ 42%. On the other hand, using the values Δginh 10 mg kg
1  ¼
190% and ΔgKCC2 100 mg kg
1  ¼ 34:5% derived above, the simulated increase in
anionic current due to the joint administration of these doses was
Ianion 1:9; 0:345ð Þ  67%. From this, we could infer that an increase of 67% in
anionic current corresponds to an analgesic effect of 42%, that is
Effect 67%ð Þ ¼ 42%.
The relationship between analgesia and ΔIanion . In order to infer the analgesia
current relationship for an arbitrary value of ΔIanion , we made the natural
assumption that the relation Effect ΔIanionð Þ is linear for low values ΔIanion but
saturating for high values. The simplest relation satisfying this assumption is;
Effect ΔIanionð Þ ¼
Max  ΔIanion
Curhalf þ ΔIanion
; ð6Þ
where Max stands for maximal possible MPA and Curhalf is the value of for which
the analgesia is equal to 50%·Max. These constants were determined using the
values Effect 67%ð Þ ¼ 42% and Effect 26%ð Þ ¼ 25% obtained above.
The relation between [CLP257] and gKCC2 and the relationship between
[L838,417] and ginh. The last step in building our mathematical model was to
infer the relations between doses of individual drug administration and the effect
on their respective effector. We inferred the relation between [CLP257] and ΔgKCC2
from the experimental dose response curve of CLP257 administered alone (Fig. 4g)
by inverting successively the effect-current relationship and the gKCC2 current
relationship. Explicitly, we have:
ΔgKCC2 ½CLP257ð Þ ¼ ΔI1anion;gKCC2 Effect
1 Exp ½CLP257ð Þð Þ  ð7Þ
where Exp ½CLP257ð Þ denotes the experimentally observed analgesia of a given
dose of CLP257, Effect−1 is the inversion of Eq. 6 and ΔI1anion;gKCC2 is the inverse of
Eq. 5 with respect to ΔgKCC2 assuming that Δginh ¼ 0. Similarly, the relation
between ½L838; 417 and Δginh was obtained by:
Δginh L838; 417½ ð Þ ¼ ΔI1anion;ginh Effect
1 Exp ½L838; 417ð Þð Þ  ð8Þ
where Exp ½L838; 417ð Þ denotes the experimentally observed analgesia of a given
dose of L838,417 (Fig. 4e) and ΔI1anion;ginh is the inverse of Eq. 5 with respect to Δginh
assuming that ΔgKCC2 ¼ 0.
Mathematical simulation of the analgesic effect of drug administration. Using
the equations defined above (Eqs. 5–8), we generated the surface graphs shown in
(Fig. 6d, e) under two distinct assumptions: the common effector assumption and
the distinct mechanisms assumption (see schematic representations in (Fig. 6d, e).
1) The common effector assumption. Under this assumption, the simulated the
effect of joint L838,417 and CLP257 application is computed by first transforming
the dose of CLP257 into a dose of L838,417 yielding an equivalent effect. The dose
of L838,417 equivalent to a dose of CLP257 was obtained by first computing the
current increase due to the administration of CLP257 and then inverting the
L838,417-current relation. Explicitly, we computed:
DoseeqL838;417 CLP257½ ð Þ ¼ Δg1inh ΔI1anion;ginh ΔIanion 0;ΔgKCC2ð CLP257½ Þð Þ½ 
n o
: ð9Þ
The simulated effect of joint administration of CLP257 and L838,417 under the
common effector assumption was then computed as the effect of administrating the
following dose of L838,417 alone: L838; 417½  þ DoseeqL838;417 CLP257½ ð Þ. Explicitly,
this gives:
Effectcommon L838; 417½ ; CLP257½ ð Þ
¼ Effect ΔIanion Δginh L838; 417½  þ DoseeqL838;417 CLP257½ ð Þ; 0
 h in o ð10Þ
where the functions used in the right-hand side are defined by the Eqs. 6 and 9.
Equation 10 was used to generate the common effector modeled surface in Fig. 6d.
2) The distinct effector assumption. We simulated the effect of joint CLP257
and L838,417 administrations under the assumption each drugs works on a distinct
effector namely KCC2 activity for CLP257 and ginh for L838,417. The simulated
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effect was computed of a dose of CLP257 and a dose of L838,417 is thus given by:
Effectdistinct L838; 417½ ; CLP257½ ð Þ ¼ Effect ΔIanion Δginh L838; 417½ ð Þ;ΔgKCC2ð CLP257½ Þð Þð Þ:
ð11Þ
Equation 11 was used to generate the distinct effector modeled surface in
Fig. 6e. The domains of the surface graphs in Fig. 6d, e were constrained so that the
inversions in Eqs. 5–8 are always well defined and that the equivalent dose of
L838,417 in Eq. 9 always lies within the range of experimental doses.
The quantitative values in the graphics of Fig. 6d, e obviously depend on the
specific function used to model the anionic current. However, we tried several
values of Vmean and Veff as well as replacing the ohmic formalism by the GHK
formalism and every version of the model gave a qualitative synergy.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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